[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 221
1. Chren MM, Sahay AP, Bertenthal DS, Sen S, Landefeld CS: Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol; 2007 Jun;127(6):1351-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma.
  • Quality of life is an important treatment outcome for conditions that are rarely fatal, such as cutaneous basal cell carcinoma and squamous cell carcinoma (typically called nonmelanoma skin cancer (NMSC)).
  • The main outcome was tumor-related quality of life 1 to 2 years after therapy, measured with the 16-item version of Skindex, a validated measure.
  • [MeSH-major] Carcinoma, Basal Cell / psychology. Carcinoma, Basal Cell / surgery. Quality of Life. Skin Neoplasms / psychology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Squamous Cell / psychology. Carcinoma, Squamous Cell / surgery. Emotions. Female. Follow-Up Studies. Health Status Indicators. Humans. Male. Middle Aged. Mohs Surgery. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301830.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K02 AR 02203-01
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


2. Ouyang YH: Skin cancer of the head and neck. Semin Plast Surg; 2010 May;24(2):117-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer of the head and neck.
  • The majority of skin cancers of the head and neck are nonmelanoma skin cancers (NMSC).
  • Basal cell carcinoma and squamous cell carcinoma are the most frequent types of NMSC.
  • Malignant melanoma is an aggressive neoplasm of skin, and the ideal adjuvant therapy has not yet been found, although various options for treatment of skin cancer are available to the patient and physician, allowing high cure rate and excellent functional and cosmetic outcomes.
  • Sunscreen protection and early evaluation of suspicious areas remain the first line of defense against skin cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22550432.001).
  • [ISSN] 1535-2188
  • [Journal-full-title] Seminars in plastic surgery
  • [ISO-abbreviation] Semin Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3324239
  • [Keywords] NOTNLM ; Basal cell carcinoma / Mohs' micrographic surgery / melanoma / nonmelanoma skin cancer / squamous cell carcinoma
  •  go-up   go-down


3. Kaae J, Boyd HA, Hansen AV, Wulf HC, Wohlfahrt J, Melbye M: Photosensitizing medication use and risk of skin cancer. Cancer Epidemiol Biomarkers Prev; 2010 Nov;19(11):2942-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photosensitizing medication use and risk of skin cancer.
  • Whether use of these medications affects skin cancer risk, however, is unclear.
  • METHODS: Using a cohort of all Danish residents ≥15 years old in 1995 to 2006 (n = 4,761,749) and information from Danish national registers, we examined associations between use of photosensitizing medications and risk of basal cell carcinoma, cutaneous malignant melanoma, Merkel cell carcinoma, and squamous cell carcinoma.
  • RESULTS: Users of only 2 of 19 medications for long-term use (methyldopa and furosemide) had both a ≥20% increased risk of skin cancer (compared with nonusers) and an increase in risk with increasing duration of use; these effects were limited to basal cell carcinoma and squamous cell carcinoma, respectively.
  • In contrast, 8 of 10 medications for short-term use were associated with both a ≥20% increased risk of skin cancer and an increase in risk with increasing use for at least one of the four cancers.
  • CONCLUSION: We found little evidence of an increased risk of skin cancer among users of photosensitizing medications for long-term daily use, but could not rule out the possibility that users of some photosensitizing medications for short-term use may have an increased risk of skin cancer.
  • Our study examined the effect of a wide range of photosensitizing medications on skin cancer risk and suggests that future work should focus on photosensitizing medications for short-term use.
  • [MeSH-major] Photosensitivity Disorders / chemically induced. Prescription Drugs / adverse effects. Skin Neoplasms / epidemiology. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 20861398.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prescription Drugs
  •  go-up   go-down


Advertisement
4. Vaid M, Katiyar SK: Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review). Int J Oncol; 2010 May;36(5):1053-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in life style over the past several decades including much of the time spent outdoors and the use of tanning devices for cosmetic purposes by individuals have led to an increase in the incidence of solar ultraviolet (UV) radiation-induced skin diseases including the risk of skin cancers.
  • Solar UV radiations are considered as the most prevalent environmental carcinogens, and chronic exposure of the skin to UV leads to squamous and basal cell carcinoma and melanoma in human population.
  • Silymarin is one of them and extensively studied for its skin photoprotective capabilities.
  • ), and has been shown to have chemopreventive effects against photocarcinogenesis in mouse tumor models.
  • Topical treatment of silymarin inhibited photocarcinogenesis in mice in terms of tumor incidence, tumor multiplicity and growth of the tumors.
  • It is suggested that silymarin may favorably supplement sunscreen protection, and may be useful for skin diseases associated with solar UV radiation-induced inflammation, oxidative stress and immunomodulatory effects.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1993 Apr 23;260(5107):496-7 [8097337.001]
  • [Cites] Science. 1993 Apr 23;260(5107):547-9 [8097338.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):846-8 [8388060.001]
  • [Cites] Immunol Today. 1993 Jul;14(7):335-8 [8103338.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] Photochem Photobiol. 1993 Dec;58(6):813-7 [8310001.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] Carcinogenesis. 1994 Jun;15(6):1099-103 [8020140.001]
  • [Cites] J Invest Dermatol. 1994 Aug;103(2):211-6 [8040612.001]
  • [Cites] J Leukoc Biol. 1994 Dec;56(6):769-75 [7996051.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):170-5 [7857113.001]
  • [Cites] J Immunol. 1995 May 15;154(10):5114-20 [7730617.001]
  • [Cites] J Immunol. 1995 Nov 15;155(10):4661-8 [7594465.001]
  • [Cites] Photochem Photobiol. 1995 Nov;62(5):855-61 [8570723.001]
  • [Cites] J Cell Biol. 1996 Apr;133(1):211-20 [8601609.001]
  • [Cites] J Biol Chem. 1996 Apr 5;271(14):8285-94 [8626523.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1023-30 [8640756.001]
  • [Cites] J Invest Dermatol. 1996 Jun;106(6):1187-91 [8752655.001]
  • [Cites] Photochem Photobiol. 1996 Apr;63(4):356-7 [8934734.001]
  • [Cites] Photochem Photobiol. 1996 Apr;63(4):380-3 [8934743.001]
  • [Cites] J Immunol. 1996 Dec 15;157(12):5254-61 [8955170.001]
  • [Cites] J Natl Cancer Inst. 1997 Apr 16;89(8):556-66 [9106644.001]
  • [Cites] Int J Oncol. 2002 Dec;21(6):1213-22 [12429970.001]
  • [Cites] Carcinogenesis. 2003 May;24(5):927-36 [12771038.001]
  • [Cites] Carcinogenesis. 2003 Aug;24(8):1379-88 [12807737.001]
  • [Cites] J Invest Dermatol. 2003 Oct;121(4):862-8 [14632206.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):510-7 [15009738.001]
  • [Cites] J Am Acad Dermatol. 1998 May;38(5 Pt 1):681-6 [9591810.001]
  • [Cites] J Cell Biochem Suppl. 1997;27:59-67 [9591194.001]
  • [Cites] J Invest Dermatol. 1998 Jun;110(6):966-71 [9620307.001]
  • [Cites] Br J Dermatol. 1998 Jul;139(1):3-10 [9764141.001]
  • [Cites] J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):611-25 [9777769.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):622-32 [9973210.001]
  • [Cites] Nat Med. 1999 Apr;5(4):418-22 [10202931.001]
  • [Cites] Br J Dermatol. 1999 Feb;140(2):255-8 [10233218.001]
  • [Cites] J Invest Dermatol. 1999 May;112(5):751-6 [10233767.001]
  • [Cites] J Am Acad Dermatol. 1999 May;40(5 Pt 1):697-701 [10321596.001]
  • [Cites] Am J Health Syst Pharm. 1999 Jun 15;56(12):1195-7 [10484652.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1404-13 [15831527.001]
  • [Cites] Mol Cancer Ther. 2006 Jul;5(7):1660-8 [16891451.001]
  • [Cites] J Dermatol Sci. 2007 Apr;46(1):21-30 [17289350.001]
  • [Cites] J Dermatol Sci. 2007 Dec;48(3):213-24 [17689055.001]
  • [Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):266-71 [18221354.001]
  • [Cites] J Invest Dermatol. 2009 May;129(5):1258-70 [19020550.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Feb;3(2):179-89 [20103727.001]
  • [Cites] J Exp Med. 1998 Apr 6;187(7):1133-8 [9529329.001]
  • [Cites] J Investig Dermatol Symp Proc. 1999 Sep;4(1):97-100 [10537017.001]
  • [Cites] Carcinogenesis. 1999 Nov;20(11):2117-24 [10545414.001]
  • [Cites] Cancer Lett. 1999 Dec 1;147(1-2):77-84 [10660092.001]
  • [Cites] Int Urol Nephrol. 1999;31(4):417-22 [10668934.001]
  • [Cites] J Heart Lung Transplant. 2000 Mar;19(3):249-55 [10713249.001]
  • [Cites] Liver Transpl. 2000 May;6(3):253-62 [10827224.001]
  • [Cites] Carcinogenesis. 2001 Feb;22(2):287-94 [11181450.001]
  • [Cites] Int J Oncol. 2001 Jun;18(6):1307-13 [11351267.001]
  • [Cites] J Leukoc Biol. 2001 May;69(5):719-26 [11358979.001]
  • [Cites] Photochem Photobiol. 2001 Jun;73(6):600-4 [11421064.001]
  • [Cites] Photochem Photobiol. 2001 Jun;73(6):621-9 [11421067.001]
  • [Cites] J Invest Dermatol. 2001 Jul;117(1):147-50 [11442762.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Oct 15;176(2):110-7 [11601887.001]
  • [Cites] Drugs. 2001;61(14):2035-63 [11735632.001]
  • [Cites] Photochem Photobiol. 2001 Dec;74(6):787-93 [11783934.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):314-46 [11839647.001]
  • [Cites] Carcinogenesis. 2002 Mar;23(3):499-510 [11895866.001]
  • [Cites] Sci STKE. 2003 Jan 28;2003(167):RE2 [12554854.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6349-56 [15342425.001]
  • [Cites] Arzneimittelforschung. 1968 Jun;18(6):688-96 [5755805.001]
  • [Cites] Arzneimittelforschung. 1974 Apr;24(4):466-71 [4408125.001]
  • [Cites] J Natl Cancer Inst. 1974 Nov;53(5):1333-6 [4139281.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Dec;74(12):5574-8 [271984.001]
  • [Cites] Br J Clin Pharmacol. 1978 May;5(5):431-6 [656282.001]
  • [Cites] J Immunol. 1980 Jan;124(1):445-53 [6153101.001]
  • [Cites] Br Med J. 1979 Dec 8;2(6203):1461-6 [393355.001]
  • [Cites] Scand J Gastroenterol. 1982 Jun;17(4):517-21 [6753109.001]
  • [Cites] Science. 1983 Sep 23;221(4617):1256-64 [6351251.001]
  • [Cites] Immunol Rev. 1984 Aug;80:87-102 [6237978.001]
  • [Cites] Cancer Res. 1986 May;46(5):2203-7 [3516380.001]
  • [Cites] J Hepatol. 1989 Jul;9(1):105-13 [2671116.001]
  • [Cites] J Exp Med. 1989 Oct 1;170(4):1117-31 [2529340.001]
  • [Cites] Semin Dermatol. 1990 Mar;9(1):25-31 [2203440.001]
  • [Cites] J Invest Dermatol. 1990 Oct;95(4):436-40 [2120354.001]
  • [Cites] J Invest Dermatol. 1990 Nov;95(5):530-6 [2230216.001]
  • [Cites] Pharm Res. 1991 Feb;8(2):273-7 [1902564.001]
  • [Cites] Dermatol Clin. 1991 Oct;9(4):751-5 [1934649.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8 [1946433.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7516-20 [1502162.001]
  • [Cites] J Exp Med. 1993 Apr 1;177(4):1199-204 [8096238.001]
  • (PMID = 20372777.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA105368-01; United States / NCI NIH HHS / CA / R03 CA105368; United States / NCI NIH HHS / CA / R03 CA105368-02; United States / NCI NIH HHS / CA / CA105368-02; United States / NCI NIH HHS / CA / CA105368-01; United States / NCI NIH HHS / CA / CA105368
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antioxidants; 0 / Carcinogens; 0 / Plant Extracts; 0 / Silymarin
  • [Other-IDs] NLM/ NIHMS184206; NLM/ PMC2852174
  •  go-up   go-down


5. Rollison DE, Pawlita M, Giuliano AR, Iannacone MR, Sondak VK, Messina JL, Cruse CW, Fenske NA, Glass LF, Kienstra M, Michael KM, Waterboer T, Gheit T, Tommasino M: Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers. Int J Cancer; 2008 Nov 15;123(10):2337-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers.
  • Cutaneous human papillomavirus (HPV) may be associated with the development of nonmelanoma skin cancer (NMSC), as suggested by reports of HPV DNA in NMSC tumors.
  • NMSC tumor tissue was obtained from 20 patients with pathology-confirmed basal or squamous cell carcinoma of the skin, in addition to several normal tissues, including eyebrow hairs, normal skin swabs obtained using multiple techniques, normal skin punch and shave biopsies, and serum for antibody measurement.
  • Using HPV DNA in tumor tissues as a gold standard, sensitivity and specificity were calculated for each measure of HPV infection in normal tissues. beta-Papillomavirus DNA was observed in tumor tissues in 60% of patients.
  • The normal skin punch biopsy demonstrated optimal sensitivity (75%) and specificity (75%).
  • [MeSH-major] Biomarkers / metabolism. Papillomavirus Infections / virology. Skin Diseases, Viral / virology. Skin Neoplasms / virology
  • [MeSH-minor] Betapapillomavirus / isolation & purification. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / virology. Enzyme-Linked Immunosorbent Assay. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18729188.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


6. Adenis JP, Sabatier A, Robert PY: [Tumors of the eyelids in the elderly]. J Fr Ophtalmol; 2006 Jun;29(6):687-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical aspect of tumors of the eyelids is polymorphous; however, the most frequent are benign tumors such as papillomas, basal cell carcinoma, squamous cell carcinoma, meibomian gland carcinoma, and melanomas.
  • An important step in the management of the malignant types is to try to establish clear margins through histopathologic techniques: the Mohs technique, the rapid fixation technique, and the frozen section method are the most frequent technical tools used today.
  • For the most malignant tumors such as malignant melanoma and Merkel cell tumor, lymph sentinel biopsy is a recent, valuable tool, but its benefit needs to be confirmed in large series.
  • [MeSH-major] Eyelid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885901.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 13
  •  go-up   go-down


7. Applebaum KM, Karagas MR, Hunter DJ, Catalano PJ, Byler SH, Morris S, Nelson HH: Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire. Environ Health Perspect; 2007 Aug;115(8):1231-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire.
  • UV damage is specifically repaired by nucleotide excision repair (NER), and common genetic variants in NER may increase risk for non-melanoma skin cancer (NMSC).
  • METHODS: Incident cases of basal and squamous cell carcinoma (BCC and SCC, respectively) were identified through a network of dermatologists and pathology laboratories across New Hampshire.
  • The analysis included 880 cases of BCC, 666 cases of SCC, and 780 controls.
  • RESULTS: There was an increased BCC risk associated with high arsenic exposure among those homozygous variant for XPA [odds ratio (OR) = 1.8; 95% confidence interval (CI), 0.9-3.7].
  • For XPD, having variation at both loci (312Asn and 751Gln) occurred less frequently among BCC and SCC cases compared with controls (OR = 0.8; 95% CI, 0.6-1.0) for both case groups.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1998 Aug;106 Suppl 4:1047-50 [9703491.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):77-81 [9950243.001]
  • [Cites] Toxicol Lett. 1998 Dec 28;102-103:235-9 [10022259.001]
  • [Cites] Oncol Res. 1998;10(9):475-82 [10223623.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Aug 15;159(1):65-75 [10448126.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):295-9 [11872635.001]
  • [Cites] Environ Health Perspect. 1999 Sep;107(9):727-9 [10464073.001]
  • [Cites] Prensa Med Argent. 1964 Oct 23;51:994-8 [14231402.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1788-93 [15533908.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2433-41 [15333465.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2242-6 [15598786.001]
  • [Cites] Hum Mutat. 2005 Apr;25(4):353-9 [15776433.001]
  • [Cites] Cancer Lett. 2005 May 26;222(2):205-9 [15863269.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):551-5 [10753184.001]
  • [Cites] Carcinogenesis. 2000 May;21(5):965-71 [10783319.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):874-97 [10841823.001]
  • [Cites] Pharmacology. 2000 Sep;61(3):212-27 [10971208.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1354-7 [11245433.001]
  • [Cites] Am J Epidemiol. 2001 Mar 15;153(6):559-65 [11257063.001]
  • [Cites] Carcinogenesis. 2001 Apr;22(4):593-7 [11285194.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3321-5 [11309287.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):355-60 [11319176.001]
  • [Cites] Carcinogenesis. 2001 Jun;22(6):899-904 [11375896.001]
  • [Cites] Mutat Res. 2001 Jul 1;478(1-2):159-68 [11406180.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1185-8 [11470747.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Dec 1;177(2):132-48 [11740912.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):152-5 [11782372.001]
  • [Cites] Carcinogenesis. 2002 Apr;23(4):599-603 [11960912.001]
  • [Cites] Int J Hyg Environ Health. 2002 Mar;205(1-2):85-94 [12018020.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):993-7 [12376498.001]
  • [Cites] Mutat Res. 2002 Nov 30;509(1-2):165-74 [12427537.001]
  • [Cites] J Invest Dermatol. 2003 Jan;120(1):48-55 [12535197.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):263-8 [12569548.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):505-9 [12663511.001]
  • [Cites] Toxicol Lett. 2003 Jul 20;143(2):123-31 [12749816.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):37-65 [14643412.001]
  • [Cites] Mutagenesis. 2004 Mar;19(2):143-8 [14981161.001]
  • [Cites] Carcinogenesis. 2004 May;25(5):729-34 [14688016.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1604-9 [15381933.001]
  • [Cites] J Natl Cancer Inst. 1968 Mar;40(3):453-63 [5644201.001]
  • [Cites] Beitr Pathol. 1974 Apr;151(4):384-400 [4838015.001]
  • [Cites] Can Med Assoc J. 1975 Sep 6;113(5):396-401 [125622.001]
  • [Cites] Am J Epidemiol. 1976 Dec;104(6):609-20 [998608.001]
  • [Cites] Hum Toxicol. 1983 Jan;2(1):121-33 [6840787.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5895-9 [4053060.001]
  • [Cites] J Mol Biol. 1987 Aug 20;196(4):947-50 [3681984.001]
  • [Cites] J Clin Epidemiol. 1989;42(4):317-24 [2723692.001]
  • [Cites] Mol Toxicol. 1989 Winter;2(1):1-9 [2615768.001]
  • [Cites] Biol Trace Elem Res. 1989 Jul-Sep;21:373-81 [2484616.001]
  • [Cites] Biol Met. 1991;4(4):197-200 [1777354.001]
  • [Cites] Mutagenesis. 1992 Jan;7(1):51-5 [1635456.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):493-7 [8220096.001]
  • [Cites] Mutat Res. 2005 Jul 1;574(1-2):105-11 [15914210.001]
  • [Cites] Cancer Detect Prev. 2005;29(3):209-14 [15936590.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1539-44 [15941969.001]
  • [Cites] Mutat Res. 2006 Jun;612(3):215-46 [16574468.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1193-8 [16882524.001]
  • [Cites] Carcinogenesis. 2006 Aug;27(8):1670-5 [16513681.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):672-6 [17050553.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;84:1-477 [15645577.001]
  • [Cites] Am J Epidemiol. 1994 Oct 1;140(7):598-607 [7942760.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):109-14 [7819025.001]
  • [Cites] Mamm Genome. 1996 Aug;7(8):563-74 [8679005.001]
  • [Cites] Carcinogenesis. 1997 Feb;18(2):399-405 [9054635.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):345-51 [9219571.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):589-96 [9264271.001]
  • [Cites] Epidemiology. 1997 Sep;8(5):545-50 [9270957.001]
  • [Cites] Trends Biochem Sci. 1998 Jan;23(1):1-4 [9478126.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):604-8 [9485007.001]
  • [Cites] Mutat Res. 1998 Feb;407(1):25-34 [9539978.001]
  • (PMID = 17687452.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA057494; United States / NCI NIH HHS / CA / R01CA082354; United States / NIEHS NIH HHS / ES / P42 ES007373; United States / NIEHS NIH HHS / ES / T32 ES07155; United States / NIEHS NIH HHS / ES / P42 ES07373; United States / NCI NIH HHS / CA / R01CA57494; United States / NIEHS NIH HHS / ES / T32 ES007155; United States / NCI NIH HHS / CA / R01 CA082354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Environmental Pollutants; 0 / XPA protein, human; 0 / Xeroderma Pigmentosum Group A Protein; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human; N712M78A8G / Arsenic
  • [Other-IDs] NLM/ PMC1940098
  •  go-up   go-down


8. Kimball KJ, Straughn JM, Conner MG, Kirby TO: Recurrent basosquamous cell carcinoma of the vulva. Gynecol Oncol; 2006 Aug;102(2):400-2
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent basosquamous cell carcinoma of the vulva.
  • BACKGROUND: Basosquamous cell carcinoma (BSC) of the vulva is a rare entity with interesting prognostic and therapeutic implications.
  • CONCLUSION: BSC is a rare disorder of the vulva.
  • The metastatic potential of this tumor is not fully understood, but likely is intermediate between squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Carcinoma, Basosquamous / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624392.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Costantino D, Lowe L, Brown DL: Basosquamous carcinoma-an under-recognized, high-risk cutaneous neoplasm: case study and review of the literature. J Plast Reconstr Aesthet Surg; 2006;59(4):424-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for basosquamous carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma-an under-recognized, high-risk cutaneous neoplasm: case study and review of the literature.
  • Basosquamous carcinoma of the skin is a relatively rare cutaneous neoplasm that has been shown to have significant metastatic potential.
  • Histopathologists debate whether these lesions arise de novo or differentiate from pre-existing basal cell carcinomas.
  • We present a case in which a longstanding lesion initially diagnosed as basal cell carcinoma was later found to have basosquamous histology and regional metastases.
  • Review of the literature reveals a metastatic rate greater than that of basal cell and squamous cell carcinoma, and identifies several important characteristics that impact prognosis after surgical resection.
  • For physicians treating carcinomas of the skin, it is important to understand the natural history and proper treatment of this aggressive neoplasm.
  • [MeSH-major] Carcinoma, Basosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Foot Diseases / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Lymphatic Metastasis / diagnosis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756261.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 15
  •  go-up   go-down


10. Miller KL, Karagas MR, Kraft P, Hunter DJ, Catalano PJ, Byler SH, Nelson HH: XPA, haplotypes, and risk of basal and squamous cell carcinoma. Carcinogenesis; 2006 Aug;27(8):1670-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XPA, haplotypes, and risk of basal and squamous cell carcinoma.
  • Nucleotide excision repair (NER) is instrumental in removing DNA lesions caused by ultraviolet (UV) radiation, the dominant risk factor for keratinocyte carcinoma, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • We evaluated whether BCC or SCC risk was influenced by the A23G single nucleotide polymorphism (SNP) in Xeroderma pigmentosum group A (XPA), which codes for an essential protein in NER.
  • We also investigated whether haplotypes of XPA, determined by seven haplotype-tagging SNPs, better define susceptibility to keratinocyte carcinoma.
  • Incident cases of BCC and SCC from New Hampshire were identified through dermatologists and pathology laboratories.
  • Cases of BCC (886) and of SCC (682) were compared with controls (796).
  • Using GG as the reference, the A allele was less frequent among cases of BCC (OR(AG) = 0.82, 95% CI (0.66, 1.01); OR(AA)= 0.74, 95% CI (0.53, 1.03); trend test P = 0.03) and SCC (OR(AG) = 0.85, 95% CI (0.67, 1.07); OR(AA) = 0.74, 95% CI (0.52, 1.05); trend test P = 0.05) than controls.
  • Risk from > or =3 severe sunburns was elevated for those with the GG genotype only, and this interaction was nearly significant for BCC (P = 0.07).
  • Using a haplotype analysis identifying seven common XPA haplotypes indicated that the A23G polymorphism alone captured the differences in susceptibility to keratinocyte carcinoma.
  • The common G allele of the A23G polymorphism was associated with an increased risk of BCC and SCC and this polymorphism appeared to be the determining polymorphism in XPA that alters cancer susceptibility.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Haplotypes / genetics. Skin Neoplasms / genetics. Xeroderma Pigmentosum Group A Protein / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16513681.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA006515; United States / NCI NIH HHS / CA / R01 CA082354; United States / NCI NIH HHS / CA / R01CA57494; United States / NIEHS NIH HHS / ES / T32 ES007155
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / XPA protein, human; 0 / Xeroderma Pigmentosum Group A Protein
  •  go-up   go-down


11. Szeimies RM, Karrer S, Bäcker H: [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma]. Hautarzt; 2005 May;56(5):430-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma].
  • [Transliterated title] Therapieoptionen bei epithelialen Hauttumoren Aktinische Keratosen, Morbus Bowen, spinozelluläres Karzinom und Basalzellkarzinom.
  • There has been worldwide a significant rise in the incidence of epithelial skin tumors and their precursors in the past years with an increased number of younger patients affected.
  • In the following article different therapeutic approaches for actinic keratoses, Bowen's disease, basal cell carcinoma and squamous cell carcinoma are presented and analysed.
  • [MeSH-major] Risk Assessment / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Bowen's Disease / diagnosis. Bowen's Disease / therapy. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Cryotherapy / methods. Curettage / methods. Humans. Keratosis / diagnosis. Keratosis / therapy. Practice Guidelines as Topic. Practice Patterns, Physicians'. Risk Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]
  • [Cites] Br J Dermatol. 2001 Mar;144(3):567-74 [11260016.001]
  • [Cites] Int J Dermatol. 2001 Nov;40(11):709-13 [11737438.001]
  • [Cites] J Am Acad Dermatol. 2001 Mar;44(3):462-70 [11209116.001]
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8 [10459115.001]
  • [Cites] Dermatologica. 1979;158(5):368-72 [437226.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):687-92 [15357755.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] Clin Exp Dermatol. 1999 Jul;24(4):338-9 [10457144.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Apr;15(4):424-31 [2925988.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):258-62 [12140473.001]
  • [Cites] J Am Acad Dermatol. 1982 Nov;7(5):631-2 [7142470.001]
  • [Cites] J Drugs Dermatol. 2004 Jul-Aug;3(4):401-7 [15303784.001]
  • [Cites] Dermatol Surg. 2004 Sep;30(9):1214-8 [15355363.001]
  • [Cites] Br J Dermatol. 1999 Oct;141(4):633-41 [10583109.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Mar;17(2):167-70 [12705745.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:43-9 [14616349.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):148-56 [15270884.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Arch Dermatol. 2002 Nov;138(11):1498-502 [12437457.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 1):517-20 [15056141.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] J Am Acad Dermatol. 1998 Mar;38(3):438-42 [9520026.001]
  • [Cites] Australas J Dermatol. 2000 Feb;41(1):19-30 [10715896.001]
  • [Cites] J Am Acad Dermatol. 2004 Oct;51(4):547-55 [15389189.001]
  • [Cites] Clin Dermatol. 2001 May-Jun;19(3):328-38 [11479045.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1284-5 [15492200.001]
  • [Cites] J Dermatolog Treat. 2003 Jun;14(2):99-106 [12775317.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] Br J Dermatol. 2003 Mar;148(3):539-43 [12653747.001]
  • [Cites] J Am Acad Dermatol. 1997 Jan;36(1):72-7 [8996264.001]
  • [Cites] Dermatol Surg. 2003 Nov;29(11):1150-3; discussion 1153 [14641346.001]
  • [Cites] Dermatol Surg. 2001 Feb;27(2):143-6 [11207687.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Br J Dermatol. 1996 Nov;135(5):766-71 [8977678.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Sep;17(9):720-6 [1820764.001]
  • [Cites] Clin Radiol. 1986 Jan;37(1):33-4 [3514075.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):714-21 [15097955.001]
  • [Cites] Clin Ther. 2002 Jun;24(6):990-1000 [12117087.001]
  • [Cites] Lasers Surg Med. 2004;34(2):114-9 [15004822.001]
  • (PMID = 15815888.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


12. Son KD, Kim TJ, Lee YS, Park GS, Han KT, Lim JS, Kang CS: Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. J Surg Oncol; 2008 Jun 1;97(7):615-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin.
  • BACKGROUND: This study evaluates several tumor-related markers to examine the expression pattern of markers according to the invasiveness and histopathologic differentiation of squamous cell carcinoma and basal cell carcinoma.
  • METHODS: Ninety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
  • RESULTS: The depth of invasion showed a correlation with CD44v6 expression of tumor cell in both squamous cell carcinoma and basal cell carcinoma (P = 0.009, P = 0.036, respectively) and with the MMP-1 expression of stromal cell in squamous cell carcinoma (P = 0.010).
  • The differentiation of squamous cell carcinoma was correlated with Ki-67 index.
  • The loss of palisading arrangement in basal cell carcinoma was correlated with the MMP-1 expression of stromal cells (P = 0.045).
  • CONCLUSIONS: CD44v6 and MMP-1, expressed in tumor cells and stromal cells respectively, are significant markers associated with the invasiveness of tumors in squamous cell carcinoma and basal cell carcinoma of the skin and that it will be helpful to evaluate the invasiveness by measuring the expression of these markers.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / biosynthesis. Female. Genes, erbB-1. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 3 / biosynthesis. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404670.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


13. Arshad AR, Azman WS, Kreetharan A: Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma. Head Neck; 2008 Apr;30(4):544-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma.
  • Its association with basal cell carcinoma is well known.
  • METHOD: This is a case report of sebaceous carcinoma complicated by both basal cell carcinoma and squamous cell carcinoma.
  • RESULTS: The behavior of this tumor is very aggressive, resulting in poor prognosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Sebaceous of Jadassohn / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972311.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kunte C, Konz B: [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin]. Hautarzt; 2007 May;58(5):419-26
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin].
  • [Transliterated title] Aktuelle Therapieempfehlungen für das Basalzellkarzinom und Plattenepithelkarzinom der Haut.
  • The incidence of the most common tumors of the skin, basal cell carcinoma and squamous cell carcinoma, has risen rapidly in recent years.
  • They must be able to develop therapeutic strategies adapted to the tumor and the patient.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Invasiveness. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Prognosis. Radiotherapy, Adjuvant. Skin / pathology. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]
  • [Cites] Facial Plast Surg. 1997 Apr;13(2):79-82 [9243982.001]
  • [Cites] Hautarzt. 2005 May;56(5):430-40 [15815888.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] J Dermatol Surg Oncol. 1994 May;20(5):350 [8176049.001]
  • [Cites] Recent Results Cancer Res. 2002;160:219-24 [12079216.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):915-9 [9041153.001]
  • [Cites] BMJ. 2004 Sep 25;329(7468):705 [15364703.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):218-22 [15202839.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):91-5 [17190625.001]
  • [Cites] Br J Dermatol. 2006 Jun;154(6):1202-3 [16704658.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Sep;20(8):926-30 [16922939.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Mar;4(3):260-2 [16626324.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Jul;17(7):574-8 [1860987.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] Hautarzt. 1975 Dec;26(12):647-50 [1213885.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 May;4(5):441-3 [16686614.001]
  • [Cites] Hautarzt. 1995 Sep;46(9):607-14 [7591764.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12 (6):569-72 [12459530.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Recent Results Cancer Res. 2002;160:240-5 [12079219.001]
  • (PMID = 17443305.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 31
  •  go-up   go-down


15. Skaria AM: Recurrence of basosquamous carcinoma after Mohs micrographic surgery. Dermatology; 2010;221(4):352-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of basosquamous carcinoma after Mohs micrographic surgery.
  • BACKGROUND: The recurrence rate of basal cell carcinoma (BCC) after Mohs micrographic surgery (MMS) is well documented.
  • SUBJECTS AND METHODS: We investigated 1,000 cases of epidermal tumors in a private center of MMS including BCC, squamous cell carcinoma and basosquamous carcinoma (BSC) treated by MMS from 1998 to 2007 in a retrospective study.
  • [MeSH-major] Carcinoma, Basosquamous / surgery. Mohs Surgery. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / surgery. Female. Humans. Incidence. Male. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20924160.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


16. Rodríguez-Domínguez FJ, Hernández-Gil J, Segarra Fenoll JD, Hernández-Gil A: [Facial mutilant basosquamous carcinoma]. An Otorrinolaringol Ibero Am; 2007;34(6):549-55
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Facial mutilant basosquamous carcinoma].
  • [Transliterated title] Carcinoma basoescamoso mutilante en región facial.
  • Basosquamous carcinoma is a rare epithelial malignant neoplasm with clinical and biological features of both basal and squamous cell carcinoma.
  • This neoplasm has been characterized for years as a variant of basal cell carcinoma, although now it is widely accepted as a clinical entity.
  • The most important features of basosquamous carcinoma are its great local aggressiveness, high frequency of recurrences and its metastatic potential.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Head and Neck Neoplasms / pathology. Palliative Care / methods
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Face. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293774.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


17. Love WE, Bernhard JD, Bordeaux JS: Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol; 2009 Dec;145(12):1431-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
  • OBJECTIVES: To conduct a systematic review to determine clearance rates and adverse effects of topical imiquimod or fluorouracil therapy in the treatment of nonmelanoma skin cancers such as basal (BCC) and squamous cell carcinoma (SCC), and to develop recommendations for the use of topical imiquimod or fluorouracil to treat BCC and SCC.
  • STUDY SELECTION: Prospective, retrospective, and case studies in English containing a minimum of 4 subjects and a 6-month follow-up or posttreatment histologic evaluation.
  • DATA EXTRACTION: We calculated the rate of clearance and adverse effects for BCC subtypes and invasive and in situ SCC treated with topical imiquimod or fluorouracil.
  • Imiquimod use produced the following clearance rates: 43% to 100% for superficial BCC, 42% to 100% for nodular BCC, 56% to 63% for infiltrative BCC, 73% to 88% for SCC in situ, and 71% for invasive SCC.
  • Fluorouracil use produced the following clearance rates: 90% for superficial BCC and 27% to 85% for SCC in situ.
  • CONCLUSIONS: Evidence supports the use of topical imiquimod as monotherapy for superficial BCC and topical fluorouracil as monotherapy for superficial BCC and SCC in situ.
  • [MeSH-major] Aminoquinolines / pharmacokinetics. Antineoplastic Agents / pharmacokinetics. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Fluorouracil / pharmacokinetics. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026854.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 47
  •  go-up   go-down


18. Puizina-Ivić N, Sapunar D, Marasović D, Mirić L: An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis. Coll Antropol; 2008 Oct;32 Suppl 2:61-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis.
  • The Bcl-2 protein has been shown to suppress cell death and protects cell against apoptosis induced by different death-inducing signals.
  • In this study the authors have analyzed imunohistochemically the expression of Bcl-2 protein in the histopathological variants of the most common malignant tumors of the skin--basal cell carcinoma (BCC) and squamous cell tumor (SCC), as well as in the precancerous lesion actinic keratosis (AK) and in benign tumor seborrheic keratosis (SK).
  • Bcl-2 expression in solid, adenoid and cystic variants of BCC exhibited immunoreactivity of tumor stroma with more intense staining among peripheral palisading cells.
  • Among SCC in all samples, tumor tissue lack to express Bcl-2 positivity.
  • In cases of hypertrophic and atrophic variants of AK, Bcl-2 expression was confined to basal cell layer, as well as in one case of hypertrophic variant in suprabasal cells.
  • In three histological variants of SK expresseion of Bcl-2 protein was in areas of basaloid proliferation, while in areas of squamous differentiation was negative.
  • In clonal variant immunostaining was positive among cells in characteristic "nests" Distribution of Bcl-2 protein expression in solid, adenoid and cystic variant of BCC showed that peripheral proliferating cells are protected against apoptosis what permits tumor growth.
  • In morpheaform variant reduced amount of Bcl-2 expression indicated that this variant of BCC has increased cell proliferation, and in practice shows tendency for recurrence and difficulties to eradicate.
  • Bcl-2 expression supports the observation that tumor cells are derived from basal keratinocytes.
  • In SCC, lack of Bcl-2 expression indicates that origin of tumor cells is from more differentiated suprabasal keratinocytes.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis, Actinic / metabolism. Keratosis, Seborrheic / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin Neoplasms / metabolism


19. Fantini F, Gualdi G, Cimitan A, Giannetti A: Metastatic basal cell carcinoma with squamous differentiation: report of a case with response of cutaneous metastases to electrochemotherapy. Arch Dermatol; 2008 Sep;144(9):1186-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma with squamous differentiation: report of a case with response of cutaneous metastases to electrochemotherapy.
  • BACKGROUND: Metastatic basal cell carcinoma is a rare disease with poor prognosis.
  • Electrochemotherapy is a recently described therapy that relies on the permeation of cancer cell membranes by electrical pulses to enhance cytotoxic drug penetration.
  • It has been successfully used in the treatment of primary and metastatic skin cancers.
  • We report a case of metastatic basal cell carcinoma in which electrochemotherapy was effective in inducing local regression of skin metastases.
  • OBSERVATIONS: A 75-year-old man presented with a pigmented, deeply infiltrating nodule in the right axilla manifesting as basal cell carcinoma with squamous differentiation at histopathologic examination.
  • Three successive sessions of electrochemotherapy with bleomycin sulfate were then performed on isolated skin metastases.
  • Conclusion Electrochemotherapy is an effective and well-tolerated adjunct to the therapeutic options in metastatic basal cell carcinoma, characterized by an advantageous risk-benefit ratio and minimal downtime.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Electrochemotherapy. Skin Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Cell Differentiation. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794464.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


20. Sedda AF, Rossi G, Cipriani C, Carrozzo AM, Donati P: Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Clin Exp Dermatol; 2008 Nov;33(6):745-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are among the most common cancers in humans.
  • We describe a new treatment for BCC and SCC.
  • METHODS: In total, 53 patients with histologically confirmed diagnosis of BCC and of SCC were enrolled for the treatment.
  • CONCLUSION: The results indicated that brachytherapy is an effective treatment for BCC and SCC.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Facial Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Skin Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681873.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ointments; 7440-15-5 / Rhenium
  •  go-up   go-down


21. Ball EA, Hussain M, Moss AL: Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review. Clin Exp Dermatol; 2005 May;30(3):259-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review.
  • The development of a basal cell carcinoma within a naevus sebaceous of Jadassohn (NSJ) has commonly been reported.
  • However, the development of a squamous cell carcinoma (SCC) is rare.
  • Of these only one was a case of simultaneous occurrence of squamous and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Neoplasms, Multiple Primary / etiology. Nevus / complications. Sebaceous Gland Neoplasms / complications
  • [MeSH-minor] Adult. Humans. Male. Skin Neoplasms / etiology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15807685.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  •  go-up   go-down


22. Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch RJ, Swetter SM: Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol; 2006 Aug;142(8):976-82
Hazardous Substances Data Bank. TRICHLOROACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Facial resurfacing for nonmelanoma skin cancer prophylaxis.
  • OBJECTIVE: To determine the effect of facial skin resurfacing for treatment of actinic keratoses (AKs) and prophylaxis against new primary basal and squamous cell carcinomas in individuals with previous nonmelanoma skin cancer (NMSC) or severe photodamage.
  • SETTING: Dermatology and otolaryngology clinics of a Veterans Affairs hospital.
  • PATIENTS: Thirty-four patients with a history of facial or scalp AKs or basal or squamous cell carcinoma were enrolled.
  • Times from baseline to diagnosis of first skin cancer were compared between the treatment and control groups.
  • RESULTS: Treatment with fluorouracil, trichloroacetic acid, or carbon dioxide laser resulted in an 83% to 92% reduction in AKs (P< or =.03), a lower incidence of NMSC compared with the control group (P<.001), and a trend toward longer time to development of new skin cancer compared with the control group (P=.07).
  • CONCLUSION: All 3 modalities demonstrated benefit for AK reduction and skin cancer prophylaxis compared with controls and warrant further study in a larger trial.
  • [MeSH-major] Keratolytic Agents / administration & dosage. Keratosis / prevention & control. Low-Level Light Therapy. Skin Neoplasms / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Carbon Dioxide. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / prevention & control. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / prevention & control. Disease-Free Survival. Drug Administration Schedule. Face. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Prospective Studies. Scalp. Severity of Illness Index. Treatment Outcome. Trichloroacetic Acid / administration & dosage


23. Diepgen TL: [Epidemiology of chronic UV-damage]. J Dtsch Dermatol Ges; 2005 Sep;3 Suppl 2:S32-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas in Australia the high incidence of UV-induced skin cancer and chronic UV-damage is epidemiologically well proved, comparable figures in Europe and particularly in Germany are missing.
  • Presumably, the prevalence and incidence of actinic keratoses, basal cell carcinoma and squamous cell carcinoma are significantly underestimated.
  • The importance of chronic skin damage is discussed in accordance with new epidemiologic studies recently published in international journals.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Photosensitivity Disorders / epidemiology. Skin Neoplasms / epidemiology. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16117742.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Mancuso M, Gallo D, Leonardi S, Pierdomenico M, Pasquali E, De Stefano I, Rebessi S, Tanori M, Scambia G, Di Majo V, Covelli V, Pazzaglia S, Saran A: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis; 2009 Feb;30(2):340-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer.
  • Patched1 heterozygous mice (Ptch1(+/-)) are useful for basal cell carcinoma (BCC) studies, being remarkably susceptible to BCC induction by ultraviolet or ionizing radiation.
  • Analogously, skin carcinogenesis-susceptible (Car-S) mice are elective for studies of papilloma and squamous cell carcinoma (SCC) induction.
  • We previously reported a striking effect of gender on BCC induction in Ptch1(+/-) mice, with total resistance of females; likewise, Car-S females show increased skin tumor resistance relative to males.
  • Here, we investigated the protective role of endogenous estrogen in skin keratinocyte tumorigenesis.
  • Control (CN) and ovariectomized Ptch1(+/-) or Car-S females were irradiated for BCC induction or topically treated with chemical carcinogens for SCC induction.
  • Susceptibility to BCC or SCC was dramatically increased in ovariectomized Ptch1(+/-) and Car-S females and restored to levels observed in males.
  • Remarkably, progression of initially benign papillomas to malignant SCC occurred only in ovariectomized Car-S females.
  • We explored the mechanisms underlying tumor progression and report overexpression of estrogen receptor (ER)-alpha, downregulation of ERbeta and upregulation of cyclin D1 in papillomas from ovariectomized Car-S relative to papillomas from CN females.
  • Thus, an imbalanced ERalpha/ERbeta expression may be associated with estrogen-mediated modulation of non-melanoma skin carcinogenesis, with a key role played by cyclin D1.
  • Our findings underscore a highly protective role of endogenous estrogen against skin tumorigenesis by diverse agents in two independent mouse models of skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Estrogens / physiology. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Cyclin D1 / metabolism. Disease Models, Animal. Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Female. Male. Mice. Neoplasms, Radiation-Induced / metabolism. Neoplasms, Radiation-Induced / pathology. Ovariectomy. Papilloma / metabolism. Papilloma / pathology. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Ultraviolet Rays


25. Dhouib H, Mnejja M, Ayadi L, Hammami B, Boudawara T, Ghorbel A: [Cutaneous basosquamous carcinoma]. Ann Otolaryngol Chir Cervicofac; 2009 Mar;126(1):25-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous basosquamous carcinoma].
  • [Transliterated title] Carcinome basocellulaire métatypique.
  • INTRODUCTION: Basosquamous carcinoma is a rare entity that essentially affects the head and neck region in male patients.
  • The authors present the clinical signs and progression as well as the therapeutic consequences of this disease through two observations.
  • CASE REPORT 1: A 41-year-old man presented with basosquamous carcinoma of the right temporoparietal region treated initially with surgery alone.
  • Five years later, he was operated on for a local and lymph node recurrence followed by radiation therapy, stabilizing the disease for 4 years; subsequently a second recurrence with metastasis to the chest area occurred.
  • The patient died 10 years after the onset of his disease of diffuse pneumopathy with severe septicemia.
  • CASE REPORT 2: A 71-year-old man presented retroauricular basosquamous carcinoma at first treated with wide resection, but the surgical limits were invaded.
  • DISCUSSION: Basosquamous carcinoma is characterized by its severe aggression and its tendency to recur.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / secondary. Fatal Outcome. Humans. Lung Neoplasms / secondary. Male. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261262.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


26. Skroza N, Panetta C, Schwartz RA, Balzani A, Rota C, Buccheri EM, Alfano C, Innocenzi D: Giant meta-typical carcinoma: an unusual tumor. Acta Dermatovenerol Croat; 2006;14(1):46-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant meta-typical carcinoma: an unusual tumor.
  • Meta-typical carcinoma (MTC) or basosquamous carcinoma is a remarkable malignancy with features of both basal and squamous cell carcinoma.
  • It is typically located on the back and face, often with clinical features of basal cell carcinoma but tending to be more aggressive with enhanced prospects of lymph node or distant metastases.
  • Our report describes a huge neglected MTC of the back of ten-year duration, a giant ulcero-vegetative tumor measuring 20 x 25 cm.
  • Histologic examination of specimens from the margins and periphery revealed aspects of both basal and squamous cell carcinoma, while the ulcerated center showed sclerotic tissue without tumor.
  • This may have been related to an intense inflammatory host response with elimination of neoplastic tissue and consequent local sclerosis evident in the central tumor-free portion.
  • This central tumor regression is to our knowledge a unique finding in MTC.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603102.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


27. Downs N, Parisi A: Measurements of the anatomical distribution of erythemal ultraviolet: a study comparing exposure distribution to the site incidence of solar keratoses, basal cell carcinoma and squamous cell carcinoma. Photochem Photobiol Sci; 2009 Aug;8(8):1195-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurements of the anatomical distribution of erythemal ultraviolet: a study comparing exposure distribution to the site incidence of solar keratoses, basal cell carcinoma and squamous cell carcinoma.
  • The UV exposures were compared with existing data detailing the anatomical distribution of basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and solar keratoses (SK).
  • Surface UV exposures to unprotected skin surfaces have been presented for each of the face, neck, arm, hand and leg assessing a total of 1453 body sites (2491 measurements).
  • Further analysis with existing facial BCC and SK density data did not however show a direct relationship with the measured UV exposures highlighting the importance of other factors influencing the causation and localisation of facial NMSC.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Keratosis / epidemiology. Skin / pathology. Ultraviolet Rays

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639123.001).
  • [ISSN] 1474-905X
  • [Journal-full-title] Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
  • [ISO-abbreviation] Photochem. Photobiol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


28. Weinstock MA: Controversies in the public health approach to keratinocyte carcinomas. Br J Dermatol; 2006 May;154 Suppl 1:3-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in the public health approach to keratinocyte carcinomas.
  • Keratinocyte carcinomas are very common cancers in fair-skinned populations throughout the world.
  • The term 'keratinocyte carcinoma' includes basal and squamous cell carcinoma of the skin, but not other cancers that may be included under the more ambiguous term 'nonmelanoma skin cancer'.
  • Mortality from keratinocyte carcinoma reveals distinct patterns suggestive of an important role of human papilloma virus infection.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712708.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Number-of-references] 12
  •  go-up   go-down


29. Kolm I, Hofbauer G, Braun RP: [Early diagnosis of skin cancer]. Ther Umsch; 2010 Sep;67(9):439-46
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early diagnosis of skin cancer].
  • The skin is the most affected organ by cancer.
  • The incidence rates of skin cancer are steadily increasing, both for melanoma and non-melanoma skin cancers (squamous cell carcinoma, basal cell carcinoma).
  • Over 90 % of the death cases from skin cancers attribute to melanoma.
  • In the last years a number of new non invasive techniques for the early diagnosis of melanoma have been developed which are superior to the naked eye examination.
  • In this overview article we present some non-invasive diagnostic techniques like total body photography, digital dermoscopy and confocal microscopy which in addition to dermoscopy assist the dermatologist in differentiating nevi from early melanomas.Non-melanoma skin cancer can be prevented by accurate sun protection.
  • Early squamous cell carcinomas and basal cell carcinomas can be treated either invasively or non-invasively with excellent prognosis.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / prevention & control. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / prevention & control. Melanoma / diagnosis. Melanoma / prevention & control. Precancerous Conditions / diagnosis. Precancerous Conditions / prevention & control. Skin Neoplasms / diagnosis. Skin Neoplasms / prevention & control
  • [MeSH-minor] Dermoscopy. Early Diagnosis. Humans. Microscopy, Confocal. Photography. Risk Factors. Skin / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20806172.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


30. Leiter U, Garbe C: [Skin cancer in organ transplant patients. Epidemiology and management]. Hautarzt; 2010 Mar;61(3):207-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin cancer in organ transplant patients. Epidemiology and management].
  • Skin cancer is the most common cancer, representing 40-50% of post transplant malignancies.
  • In the first 10 years post transplantation, some 15%-40% of patients develop skin cancer, primarily squamous cell carcinoma and basal cell carcinoma, but also melanoma, Merkel cell carcinoma and virally-induced Kaposi sarcoma.
  • The management of skin cancer includes secondary prophylaxis and address attention to areas of widespread actinic damage, usually with topical agents.
  • In high risk skin cancer or metastatic disease a substantial reduction in immunosuppression to switching to mTOR inhibitors appears to substantially improve the prognosis.
  • The management of the individual tumor types is discussed; in general it follows the current guidelines.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Immunosuppressive Agents / administration & dosage. Organ Transplantation / statistics & numerical data. Postoperative Complications / epidemiology. Postoperative Complications / prevention & control. Skin Neoplasms / epidemiology. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2008 Apr;18(2):152-60 [18337653.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S15-6 [18801136.001]
  • [Cites] Am J Transplant. 2008 Sep;8(9):1891-900 [18786232.001]
  • [Cites] Curr Opin Oncol. 2009 May;21(3):232-7 [19370807.001]
  • [Cites] Transplantation. 1999 Dec 15;68(11):1717-21 [10609948.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):307 [10642700.001]
  • [Cites] Br J Dermatol. 2000 Sep;143(3):513-9 [10971322.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S2-4 [18801139.001]
  • [Cites] ScientificWorldJournal. 2008 Sep 21;8:909-19 [18836658.001]
  • [Cites] Br J Dermatol. 2007 May;156 Suppl 3:40-2 [17488405.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5):783-90 [16243126.001]
  • [Cites] Am J Transplant. 2006 Sep;6(9):2164-8 [16780549.001]
  • [Cites] Transplantation. 2009 Aug 27;88(4):597-8 [19696647.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):1-12 [17520670.001]
  • [Cites] Dermatol Surg. 2009 Oct;35(10):1567-72 [19681993.001]
  • [Cites] Am J Transplant. 2008 Nov;8(11):2192-8 [18782290.001]
  • [Cites] Dermatol Surg. 2002 Feb;28(2):113-7; discussion 117 [11860419.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]
  • [Cites] Transplantation. 2006 Dec 27;82(12):1792-3 [17198278.001]
  • [Cites] Br J Dermatol. 2008 Jul;159(1):35-48 [18593385.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Am J Transplant. 2004 Jun;4(6):905-13 [15147424.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S19-24 [18801138.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S9-S14 [18801142.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S5-8 [18801141.001]
  • [Cites] Transplantation. 1990 Mar;49(3):506-9 [2316011.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Sep;5(9):510-1 [18679393.001]
  • [Cites] J Am Acad Dermatol. 2008 Sep;59(3):405-17 [18556089.001]
  • [Cites] Transplant Proc. 1988 Jun;20(3 Suppl 3):885-92 [3388524.001]
  • [Cites] Melanoma Res. 2008 Feb;18(1):61-7 [18227710.001]
  • [Cites] Swiss Med Wkly. 2009 Jul 25;139(29-30):407-15 [19680830.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] Transplantation. 1997 Sep 15;64(5):669-73 [9311700.001]
  • [Cites] J Clin Microbiol. 2001 Feb;39(2):506-8 [11158097.001]
  • [Cites] Br J Dermatol. 2006 Aug;155(2):451-4 [16882188.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2659-65 [16763280.001]
  • [Cites] Transplantation. 2004 Feb 27;77(4):574-9 [15084938.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:25-31 [18067628.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):622-7 [15061846.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Jun;19(5):365-6 [17379490.001]
  • [Cites] Br J Dermatol. 2007 Dec;157(6):1183-8 [17916206.001]
  • [Cites] Arch Dermatol. 2001 Apr;137(4):459-63 [11295926.001]
  • (PMID = 20145902.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


31. Dawe RS: Treatment options for non-melanoma skin cancer. G Ital Dermatol Venereol; 2009 Aug;144(4):453-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for non-melanoma skin cancer.
  • Non melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma) are becoming more common.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755949.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 38
  •  go-up   go-down


32. Dixon A, Rosengren H, Connelly T, Dixon J: Education in skin cancer management--assessing knowledge and safety. Aust Fam Physician; 2009 Jul;38(7):557-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Education in skin cancer management--assessing knowledge and safety.
  • BACKGROUND: General practitioners manage the majority of skin cancers in Australia.
  • There are a range of training opportunities for, and certifications in, skin cancer management.
  • METHOD: Between 15 June and 25 June 2008, an online examination was placed on the Australasian College of Skin Cancer Medicine website.
  • Thirty questions were asked pertaining to the management of a hypothetical case study including melanoma, basal cell carcinoma and squamous cell carcinoma.
  • Two days of training may not make doctors sufficiently safe in skin cancer management; it appeared to improved knowledge, but not to a point where unsafe practice was eliminated.
  • [MeSH-major] Family Practice / education. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575076.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


33. Leverkus M, Finner AM, Pokrywka A, Franke I, Gollnick H: Metastatic squamous cell carcinoma of the ankle in long-standing untreated acrodermatitis chronica atrophicans. Dermatology; 2008;217(3):215-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic squamous cell carcinoma of the ankle in long-standing untreated acrodermatitis chronica atrophicans.
  • Occasionally, B-cell lymphoma may develop in these patients, and additional neoplastic complications such as basal cell carcinoma or squamous cell carcinoma (SCC) have been reported once each over the past 60 years.
  • [MeSH-major] Acrodermatitis / complications. Borrelia burgdorferi. Carcinoma, Squamous Cell / etiology. Lyme Disease / complications. Skin Neoplasms / etiology
  • [MeSH-minor] Aged, 80 and over. Ankle. Chronic Disease. Female. Humans. Neoplasm Metastasis


34. Heneghan MK, Hazan C, Halpern AC, Oliveria SA: Skin cancer coverage in a national newspaper: a teachable moment. J Cancer Educ; 2007;22(2):99-104
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer coverage in a national newspaper: a teachable moment.
  • BACKGROUND: The objectives of this study were to (1) identify the number of published articles related to skin cancer in The New York Times newspaper from 1980-2004;.
  • (2) assess the content of the articles related to skin cancer, and (3) examine the trends in media coverage of skin cancer over time.
  • METHODS: We performed a content analysis on articles related to skin cancer appearing in The New York Times during January 1, 1980, through December 31, 2004, using the ProQuest online content repository database and key words skin cancer.
  • We conducted an advanced focus search of all "skin cancer" articles using key words "melanoma," "squamous cell carcinoma," "basal cell carcinoma," "sunscreen," "tanning," "sunbathing," and "tanning salon".
  • RESULTS: We identified 874 published articles relating to skin cancer.
  • Coverage of other major subjects included sunscreen (11%), tanning (9%), basal cell carcinoma (7%), squamous cell carcinoma (3%), sunbathing (2%), and tanning salon (2%).
  • The remaining 37% of articles contained some mention of skin cancer, but skin cancer was not the main topic nor were any of the focus terms.
  • Over the 25-year period we examined, there was a slight upward trend in the number of skin-cancer-related articles, although we observed year-to-year variation.
  • CONCLUSIONS: Understanding how the print media portrays skin cancer issues provides valuable feedback for federal agencies and cancer organizations and may ultimately help promote skin cancer prevention and education.
  • [MeSH-major] Bibliometrics. Health Education. Journalism, Medical. Newspapers as Topic. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17605623.001).
  • [ISSN] 0885-8195
  • [Journal-full-title] Journal of cancer education : the official journal of the American Association for Cancer Education
  • [ISO-abbreviation] J Cancer Educ
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K07 CA94002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


35. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, Roenigk RK: Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA; 2005 Aug 10;294(6):681-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years.
  • CONTEXT: The incidence of nonmelanoma skin cancer is increasing rapidly among elderly persons, but little is known about its incidence in the population younger than 40 years.
  • OBJECTIVES: To estimate the sex- and age-specific incidences of basal cell carcinoma and squamous cell carcinoma in persons younger than 40 years in Olmsted County, Minnesota, and to evaluate change in incidence over time; to describe the clinical presentation, rate of recurrence and metastasis, and histologic characteristics of these tumors in this population-based sample.
  • PARTICIPANTS: Patients younger than 40 years with basal cell carcinoma or squamous cell carcinoma diagnosed between 1976 and 2003.
  • MAIN OUTCOME MEASURES: Incident basal cell carcinomas and squamous cell carcinomas and change in incidence of these tumors over time.
  • RESULTS: During the study period, 451 incident basal cell carcinomas were diagnosed in 417 patients and 70 incident squamous cell carcinomas were diagnosed in 68 patients.
  • Of these tumors, 328 were histologically confirmed basal cell carcinomas and 51 were histologically confirmed squamous cell carcinomas.
  • Overall, the age-adjusted incidence of basal cell carcinoma per 100,000 persons was 25.9 (95% confidence interval [CI], 22.6-29.2) for women and 20.9 (95% CI, 17.8-23.9) for men.
  • The incidence of basal cell carcinoma increased significantly during the study period among women (P<.001) but not men (P = .19).
  • Nodular basal cell carcinoma was the most common histologic subtype; 43.0% of tumors were solely nodular basal cell carcinoma and 11.0% had a mixed composition, including the nodular subtype.
  • The incidence of squamous cell carcinoma was similar in men and women, with an average age- and sex-adjusted incidence per 100 000 persons of 3.9 (95% CI, 3.0-4.8); the incidence of squamous cell carcinoma increased significantly over the study period among both women (P = .01) and men (P = .04).
  • CONCLUSIONS: This population-based study demonstrated an increase in the incidence of nonmelanoma skin cancer among young women and men residing in Olmsted County, Minnesota.
  • There was a disproportionate increase in basal cell carcinoma in young women.
  • This increase may lead to an exponential increase in the overall occurrence of nonmelanoma skin cancers over time as this population ages, which emphasizes the need to focus on skin cancer prevention in young adults.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278; author reply 279-81 [16418458.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):279; author reply 279-81 [16418459.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278-9; author reply 279-81 [16418456.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278; author reply 279-81 [16418457.001]
  • (PMID = 16091570.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Garcia C, Poletti E, Crowson AN: Basosquamous carcinoma. J Am Acad Dermatol; 2009 Jan;60(1):137-43
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma.
  • BACKGROUND: Basosquamous carcinoma is considered an aggressive type of basal cell carcinoma (BCC) with an increased risk of recurrence and metastases.
  • METHODS: This is a narrative review based on a MEDLINE search of articles in English and a manual search of popular dermatology textbooks to define basosquamous carcinoma, its incidence, clinical behavior, and treatment of choice.
  • RESULTS: There are no specific clinical features to distinguish basosquamous carcinoma from other BCC types and the diagnosis is made only after biopsy.
  • There are several histologic definitions of basosquamous carcinoma ranging from a characteristic combination of BCC and squamous cell carcinoma with or without a transition zone, to any BCC with evidence of keratinization.
  • The authors confine the use of the term to an infiltrative growth BCC with areas of keratinization and/or intercellular bridge formation in the setting of a prototypic proliferative stromal reaction.
  • The term "metatypical basal cell carcinoma" is considered a synonym but its use is discouraged for the reasons outlined.
  • The reported incidence of basosquamous carcinoma ranges from 1.2% to 2.7%.
  • The aggressive biological behavior and clinical course distinguish basosquamous carcinoma from other forms of BCC.
  • CONCLUSION: The terminology surrounding basosquamous carcinoma is confusing and there is a need for more uniform language.
  • Data regarding the incidence, recurrence, and metastasis rates of basosquamous carcinoma are based mostly on retrospective series with a limited number of cases.
  • We conclude that although the incidence of basosquamous carcinoma is unknown, there is a literature precedent suggesting more aggressive biological behavior.
  • We believe that complete surgical excision is the preferred approach, and that basosquamous carcinoma is an ideal candidate lesion for Mohs micrographic surgery.
  • [MeSH-major] Carcinoma, Basosquamous. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for basosquamous carcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19103364.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


37. Wells MJ, Taylor RS: Mohs micrographic surgery for penoscrotal malignancy. Urol Clin North Am; 2010 Aug;37(3):403-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific penoscrotal neoplasias discussed in this article include invasive and in situ squamous cell carcinoma, basal cell carcinoma, extramammary Paget disease, and granular cell tumor.
  • [MeSH-minor] Carcinoma, Squamous Cell / surgery. Humans. Male. Paget Disease, Extramammary / surgery. Penile Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20674695.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Rector A, Mostmans S, Van Doorslaer K, McKnight CA, Maes RK, Wise AG, Kiupel M, Van Ranst M: Genetic characterization of the first chiropteran papillomavirus, isolated from a basosquamous carcinoma in an Egyptian fruit bat: the Rousettus aegyptiacus papillomavirus type 1. Vet Microbiol; 2006 Oct 31;117(2-4):267-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic characterization of the first chiropteran papillomavirus, isolated from a basosquamous carcinoma in an Egyptian fruit bat: the Rousettus aegyptiacus papillomavirus type 1.
  • The complete genomic DNA of a novel papillomavirus (PV) was isolated from a basosquamous carcinoma on the wing of an Egyptian fruit bat (Rousettus aegyptiacus).
  • Since RaPV-1 is only distantly related to other papillomaviruses (with maximally 50% nucleotide sequence identity across the L1 open reading frame), it cannot be assigned to one of the existing papillomavirus genera and therefore represents the first member of a novel, as yet unnamed, close-to-root papillomavirus genus.
  • [MeSH-major] Carcinoma, Basosquamous / veterinary. Chiroptera / virology. Papillomaviridae / genetics. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854536.001).
  • [ISSN] 0378-1135
  • [Journal-full-title] Veterinary microbiology
  • [ISO-abbreviation] Vet. Microbiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Transposable Elements; 0 / DNA, Viral
  •  go-up   go-down


39. Flanagan AM, Rafferty G, O'Neill A, Rynne L, Kelly J, McCann J, Carty MP: The human POLH gene is not mutated, and is expressed in a cohort of patients with basal or squamous cell carcinoma of the skin. Int J Mol Med; 2007 Apr;19(4):589-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The human POLH gene is not mutated, and is expressed in a cohort of patients with basal or squamous cell carcinoma of the skin.
  • Skin cancer, the most common cancer in the general population, is strongly associated with exposure to the ultraviolet component of sunlight.
  • To investigate the relationship between DNA damage processing and skin tumour development, we determined the POLH status of a cohort of skin cancer patients.
  • In the absence of active poleta in xeroderma pigmentosum variant (XPV) patients, mutations accumulate at sites of UV-induced DNA damage, providing the initiating step in skin carcinogenesis.
  • Forty patients diagnosed with skin cancer were genotyped for polymorphisms in the POLH protein-coding sequence, using glycosylase-mediated polymorphism detection (GMPD) and direct DNA sequencing of POLH PCR products derived from white blood cell genomic DNA.
  • No POLH mutations were identified in genomic DNA from skin tumours derived from 15 of these patients.
  • As determined by RT-PCR, POLH mRNA was expressed in all normal and skin tumour tissue examined.
  • Poleta protein was also detectable by Western blotting, in two matched normal and skin tumour extracts.
  • An alternatively spliced form of POLH mRNA, lacking exon 2, was more readily detected in skin tissue than in white blood cells from the same patient.
  • Real-time PCR was used to quantify POLH expression in matched normal and skin tumour-derived mRNA from a series of patients diagnosed with either basal or squamous cell carcinoma.
  • Compared to matched normal skin tissue from the same patient, 1 of 7 SCC, and 4 of 10 BCC tumours examined showed at least a 2-fold reduction in POLH expression, while 1 of 7 SCC, and 3 of 10 BCC tumours showed at least a 2-fold increase in POLH expression.
  • Differences in gene expression, rather than sequence changes may be the main mechanism by which POLH status varies between normal and skin tumours in the population under investigation.
  • Knowledge of the POLH status in skin tumours could contribute to an understanding of the role of this gene in the development of the most common cancer in the general population.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. DNA-Directed DNA Polymerase / genetics. Gene Expression. Skin Neoplasms / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334634.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.7.7 / DNA-Directed DNA Polymerase; EC 2.7.7.7 / Rad30 protein
  •  go-up   go-down


40. Cunneen TS, Yong JL, Benger R: Lung metastases in a case of metatypical basal cell carcinoma of the eyelid: an illustrative case and literature review to heighten vigilance of its metastatic potential. Clin Exp Ophthalmol; 2008 Jul;36(5):475-7
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for metatypical basal cell carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung metastases in a case of metatypical basal cell carcinoma of the eyelid: an illustrative case and literature review to heighten vigilance of its metastatic potential.
  • Basal cell carcinoma (BCC) is an extremely common malignancy; however, unlike other skin cancers, they very rarely metastasize.
  • Here we present an unusual case of metatypical BCC of the eyelid which metastasized to the lung nine years after initial surgical treatment.
  • We include a review of the literature regarding metastatic BCC and suggest that metatypical features in primary BCC should prompt careful patient monitoring and consideration of adjuvant treatment at the time of diagnosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Eyelid Neoplasms / pathology. Lung Neoplasms / pathology. Lung Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18925916.001).
  • [ISSN] 1442-9071
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 13
  •  go-up   go-down


41. Geist DE, Garcia-Moliner M, Fitzek MM, Cho H, Rogers GS: Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management. Dermatol Surg; 2008 Dec;34(12):1642-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management.
  • BACKGROUND: Perineural invasion (PNI) by cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC) is an infrequent but not rare complication of traditionally low-morbidity skin cancers that can lead to catastrophic sequelae; 2.5% to 14% of CSCC and approximately 3% of BCC exhibit PNI.
  • MATERIALS AND METHODS: Cases of PNI treated with MMS and radiotherapy were reviewed for recurrence, disease-free follow-up, and adverse events.
  • When managing superficial skin tumors with PNI, a multidisciplinary team including a cutaneous surgeon and a radiation oncologist familiar with PNI is recommended.
  • [MeSH-major] Bell Palsy / etiology. Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / therapy. Skin Neoplasms / complications. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Mohs Surgery. Neoplasm Invasiveness. Peripheral Nerves

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bell's Palsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018830.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Marcet S: Atypical fibroxanthoma/malignant fibrous histiocytoma. Dermatol Ther; 2008 Nov-Dec;21(6):424-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical fibroxanthoma/malignant fibrous histiocytoma.
  • Atypical fibroxanthoma (AFX) is an unusual spindle cell tumor occurring on actinically damaged skin of the head and neck.
  • Clinically, it is often confused with basal cell carcinoma, squamous cell carcinoma, or even melanoma.
  • Although initially thought to be a diagnosis of exclusion histologically, newer immunostains have helped in the identification of AFX.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Histiocytoma, Malignant Fibrous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Mohs Surgery. Neoplasm Recurrence, Local


43. Perkins W: Who should have Mohs micrographic surgery? Curr Opin Otolaryngol Head Neck Surg; 2010 Aug;18(4):283-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: To review the indications for Mohs micrographic surgery in skin cancer particularly with relationship to tumours of the head and neck and any recent developments which may influence those indications in the near future.
  • RECENT FINDINGS: There is increasing evidence to support the use of Mohs micrographic surgery in the treatment of recurrent and primary basal cell carcinoma and in squamous cell carcinoma, particularly when there is evidence of perineural invasion.
  • [MeSH-major] Mohs Surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Decision Making. Dermatofibrosarcoma / surgery. Histiocytoma, Benign Fibrous / surgery. Humans. Melanoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20613530.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


44. Liutkeviciūte-Navickiene J, Mordas A, Simkute S, Bloznelyte-Plesniene L: [Fluorescence diagnostics of skin tumors using 5-aminolevulinic acid and its methyl ester]. Medicina (Kaunas); 2009;45(12):937-42
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fluorescence diagnostics of skin tumors using 5-aminolevulinic acid and its methyl ester].
  • OBJECTIVE: The incidence of malignant skin tumors is rapidly increasing.
  • Early diagnosis, determining the margins of the tumor, is extremely important to achieve good treatment results.
  • We investigated fluorescence of protoporphyrin IX in skin carcinomas.
  • The study aimed to compare the effectiveness of topical 5-aminolevulinic acid and methyl-aminolevulinate in determining the exact margins of skin tumors.
  • MATERIALS AND METHODS: Fluorescence measurements were performed in 126 patients with malignant, premalignant, and benign skin lesions for detection of the margins of squamous cell carcinoma and basal cell carcinoma.
  • 5-Aminolevulinic acid or its methyl ester was applied to the skin lesion for 2-4 h, and the data of evaluated protoporphyrin IX fluorescence were correlated with the data of morphological tissue examination.
  • RESULTS: Malignant tissue shows a specific red fluorescence when illuminated with blue-violet light, whereas no fluorescence was observed in normal skin.
  • A sensitivity of 95.4% and a specificity of 88.6% as well as positive and negative predictive values of 86.1% and 96.3%, respectively, were obtained.
  • CONCLUSIONS: Fluorescence diagnostics can be used for complete visualization of malignant skin lesions after topical application of 5-aminolevulinic acid or methyl aminolevulinate.
  • It has been shown to be highly effective in the diagnostics of malignant superficial skin lesion.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Fluorescence. Head and Neck Neoplasms / diagnosis. Photosensitizing Agents. Precancerous Conditions / diagnosis. Protoporphyrins. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Esters. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Sensitivity and Specificity. Skin / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173396.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Esters; 0 / Photosensitizing Agents; 0 / Protoporphyrins; 0 / methyl 5-aminolevulinate; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


45. Ullah T, Gurwood AS, Myers MD: Ocular metastasis of cutaneous malignant melanoma. Optometry; 2009 Oct;80(10):572-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular metastasis of cutaneous malignant melanoma.
  • Patients at greatest risk often have disseminated metastases in the setting of advanced disease.
  • Because the prognosis for orbital metastatic disease is poor, emphasis must be placed on early detection and prevention.
  • Although cutaneous malignancies include basal cell carcinoma, squamous cell carcinoma, sebaceous cell carcinoma, and malignant melanoma, the majority of cases that result in metastasis, ocular morbidity, and mortality are from sebaceous cell carcinoma and malignant melanoma.
  • Her systemic medical history was significant for the diagnosis of a cutaneous malignant melanoma.
  • Magnetic resonance imaging confirmed the diagnosis of metastatic lesions involving structures of the left orbit ultimately causing reduced visual ability.
  • Although orbital metastasis is considered a terminal finding in these cases, timely diagnosis enables, while limited, the best options for management.
  • [MeSH-major] Melanoma / secondary. Orbital Neoplasms / secondary. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Ocular melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801341.001).
  • [ISSN] 1558-1527
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Braga JC, Scope A, Klaz I, Mecca P, González S, Rabinovitz H, Marghoob AA: The significance of reflectance confocal microscopy in the assessment of solitary pink skin lesions. J Am Acad Dermatol; 2009 Aug;61(2):230-41
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of reflectance confocal microscopy in the assessment of solitary pink skin lesions.
  • BACKGROUND: Solitary pink lesions often manifest nondescript clinical and dermatoscopic primary morphologic features.
  • The differential diagnosis for pink lesions tends, therefore, to be broad, ranging from inflammatory processes to malignancy.
  • OBJECTIVE: We sought to demonstrate the use of RCM as an adjunct to the bedside diagnosis of pink lesions.
  • METHODS: We describe a series of patients with clinically and dermatoscopically equivocal pink lesions for which RCM examination allowed for a rapid and accurate diagnosis.
  • RESULTS: Lesions included basal cell carcinoma, squamous cell carcinoma, amelanotic melanoma, and inflamed seborrheic keratosis.
  • In the cases presented RCM allowed for a rapid and accurate noninvasive diagnosis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Keratosis, Actinic / pathology. Melanoma / pathology. Microscopy, Confocal. Pigmentation Disorders / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Dermoscopy / methods. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sampling Studies. Sensitivity and Specificity


47. Akyol M, Ozçelik S: Non-acne dermatologic indications for systemic isotretinoin. Am J Clin Dermatol; 2005;6(3):175-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diseases such as psoriasis, pityriasis rubra pilaris, condylomata acuminata, skin cancers, rosacea, hidradenitis suppurativa, granuloma annulare, lupus erythematosus and lichen planus have been shown to respond to the immunomodulatory, anti-inflammatory and antitumor activities of the drug.
  • Isotretinoin also helps prevent skin cancers such as basal cell carcinoma or squamous cell carcinoma.
  • A combination of systemic isotretinoin and interferon-alpha-2a may provide a more potent effect than isotretinoin alone in the prevention and treatment of skin cancers.Systemic isotretinoin may be considered as an alternative drug in some dermatologic diseases unresponsive to conventional treatment modalities.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Dermatologic Agents / therapeutic use. Isotretinoin / therapeutic use. Skin Diseases / drug therapy
  • [MeSH-minor] Acne Vulgaris / drug therapy. Anti-Bacterial Agents / therapeutic use. Condylomata Acuminata / drug therapy. Drug Therapy, Combination. Granuloma Annulare / drug therapy. Hidradenitis Suppurativa / drug therapy. Humans. Keratolytic Agents / therapeutic use. Lichen Planus / drug therapy. Lupus Erythematosus, Systemic / drug therapy. Pityriasis Rubra Pilaris / drug therapy. Psoriasis / drug therapy. Rosacea / drug therapy. Sebaceous Glands / drug effects. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943494.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Dermatologic Agents; 0 / Keratolytic Agents; EH28UP18IF / Isotretinoin
  • [Number-of-references] 133
  •  go-up   go-down


48. Asadi-Amoli F, Khoshnevis F, Haeri H, Jahanzad I, Pazira R, Shahsiah R: Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma. Am J Clin Pathol; 2010 Jul;134(1):22-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma.
  • Sebaceous carcinoma (SEB) is the most important malignant tumor of the eyelid.
  • Early diagnosis and proper treatment significantly improve the outcome.
  • SEB should be differentiated histopathologically from basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • In this study, the expression of androgen receptor (AR) in SEB, SCC, and BCC was evaluated.
  • Along with other markers and morphologic features, AR can be helpful in the diagnosis of SEB and its differentiation from SCC and BCC.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Eyelid Neoplasms / diagnosis. Receptors, Androgen / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551262.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen
  •  go-up   go-down


49. Tichý M, Ditrichová D, Brychtová S, Tichá V, Urbánek J: Double skin tumors with an atypical clinical picture. Acta Dermatovenerol Alp Pannonica Adriat; 2007 Jun;16(2):63-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double skin tumors with an atypical clinical picture.
  • The authors present a rare case of double skin tumors: acral lentiginous melanoma and metatypical carcinoma.
  • The skin biopsies showed advanced acral lentiginous melanoma on the sole and metatypical carcinoma of the lower leg.
  • Soon after the diagnosis was made, the melanoma generalized.
  • The article discusses the differential diagnosis of both leg ulcerations, correct diagnostic procedures, and characteristic features of both tumors that are important questions for general practitioners, dermatologists, and surgeons.
  • [MeSH-major] Carcinoma / diagnosis. Leg Ulcer / etiology. Melanoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Foot Ulcer / etiology. Humans. Male

  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992460.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovenia
  •  go-up   go-down


50. Zhao B, He YY: Recent advances in the prevention and treatment of skin cancer using photodynamic therapy. Expert Rev Anticancer Ther; 2010 Nov;10(11):1797-809
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the prevention and treatment of skin cancer using photodynamic therapy.
  • Recently, PDT has been widely used in treating non-melanoma skin malignancies, the most common cancer in the USA, with superior cosmetic outcomes compared with conventional therapies.
  • After treatment with ALA or methyl 5-aminolevulinate, protoporphyrin IX preferentially accumulates in the lesion area of various skin diseases, which allows not only PDT treatment but also fluorescence diagnosis with ALA-induced porphyrins.
  • Susceptible lesions include various forms of non-melanoma skin cancer such as actinic keratosis, basal cell carcinoma and squamous cell carcinoma.
  • This article summarizes the main principles of PDT and its current clinical use in the management of non-melanoma skin cancers, as well as recent developments and possible future research directions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):254-8 [16948827.001]
  • [Cites] Acta Derm Venereol. 2006;86(5):418-21 [16955186.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2006 Nov-Dec;22(6):498-9 [17117119.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):5-14 [17126737.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):89-94 [17126746.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):95-100 [17126747.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):320-8 [17223873.001]
  • [Cites] Arch Dermatol. 2007 Feb;143(2):264-5 [17310011.001]
  • [Cites] Expert Opin Drug Deliv. 2007 Mar;4(2):131-48 [17335411.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Apr;21(4):439-51 [17373968.001]
  • [Cites] Br J Dermatol. 2007 May;156(5):793-801 [17419691.001]
  • [Cites] Br J Dermatol. 2007 Jul;157(1):87-91 [17501954.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Aug;4(8):462-9 [17657251.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1131-6 [17875873.001]
  • [Cites] Photomed Laser Surg. 2007 Oct;25(5):428-35 [17975957.001]
  • [Cites] Clin Transl Oncol. 2008 Mar;10(3):148-54 [18321817.001]
  • [Cites] Br J Dermatol. 2008 May;158(5):994-9 [18341663.001]
  • [Cites] Br J Pharmacol. 2008 May;154(1):1-3 [18362894.001]
  • [Cites] J Am Chem Soc. 2008 Aug 13;130(32):10643-7 [18642918.001]
  • [Cites] Eur J Dermatol. 2008 Sep-Oct;18(5):547-53 [18693158.001]
  • [Cites] Trends Biotechnol. 2008 Nov;26(11):612-21 [18804298.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Dec 14;60(15):1627-37 [18930086.001]
  • [Cites] Br J Dermatol. 2008 Dec;159(6):1245-66 [18945319.001]
  • [Cites] Exp Dermatol. 2009 Feb;18(2):116-21 [18643849.001]
  • [Cites] Chem Commun (Camb). 2009 Mar 28;(12):1475-7 [19277361.001]
  • [Cites] Photodiagnosis Photodyn Ther. 2008 Jun;5(2):127-33 [19356643.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 May;23(5):505-16 [19175703.001]
  • [Cites] Br J Dermatol. 2009 Jun;160(6):1308-14 [19416257.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2009 Jul;29(7):992-1000 [19057023.001]
  • [Cites] Nat Med. 2009 Jul;15(7):713 [19584845.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Dec 1;241(2):163-72 [19695274.001]
  • [Cites] J Pathol. 2009 Dec;219(4):400-9 [19771562.001]
  • [Cites] Immunol Res. 2010 Mar;46(1-3):216-26 [19763892.001]
  • [Cites] Arch Dermatol. 2010 Mar;146(3):283-7 [20231499.001]
  • [Cites] Eur J Dermatol. 2000 Oct-Nov;10(7):568-75; discussion 576 [11056436.001]
  • [Cites] Ophthalmology. 2000 Dec;107(12):2314-7 [11186878.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2000 Jul;14(4):298-300 [11204521.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Mar;15(3):311-21 [11207506.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Br J Dermatol. 2001 Jun;144(6):1207-14 [11422043.001]
  • [Cites] Br J Dermatol. 2001 Sep;145(3):467-71 [11531838.001]
  • [Cites] J Photochem Photobiol B. 2001 Sep 15;62(3):140-5 [11566277.001]
  • [Cites] Photochem Photobiol. 2001 Nov;74(5):656-69 [11723793.001]
  • [Cites] J Chemother. 2001 Oct;13(5):494-502 [11760213.001]
  • [Cites] J Photochem Photobiol B. 2002 Mar;66(2):89-106 [11897509.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2005 Jun;21(3):142-9 [15888131.001]
  • [Cites] J Photochem Photobiol B. 2005 Jun 1;79(3):231-41 [15896650.001]
  • [Cites] Australas J Dermatol. 2005 Aug;46(3):196-8 [16008656.001]
  • [Cites] Br J Dermatol. 2005 Sep;153(3):672-4 [16120168.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Dec;56(6):569-77 [16001166.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):791-800 [16221049.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5 Suppl 1):S273-6 [16227107.001]
  • [Cites] Br J Dermatol. 2006 Jan;154(1):146-9 [16403108.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):542-4 [16482195.001]
  • [Cites] J Am Acad Dermatol. 2006 Mar;54(3):524-6 [16488310.001]
  • [Cites] Br J Dermatol. 2002 Apr;146(4):552-67 [11966684.001]
  • [Cites] Optom Vis Sci. 2002 Apr;79(4):218-24 [11999147.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3956-61 [12124326.001]
  • [Cites] Lasers Med Sci. 2002;17(3):173-86 [12181632.001]
  • [Cites] Clin Exp Dermatol. 2002 Sep;27(6):516-8 [12372098.001]
  • [Cites] Methods Mol Med. 2003;75:507-26 [12407761.001]
  • [Cites] J Photochem Photobiol B. 2003 Feb;69(2):121-7 [12633984.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] J Am Chem Soc. 2003 Jul 2;125(26):7860-5 [12823004.001]
  • [Cites] Mol Immunol. 2003 Jul;39(17-18):1133-6 [12835091.001]
  • [Cites] J Dermatolog Treat. 2003;14 Suppl 3:23-6 [14522638.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3591-600 [14666654.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] Dermatol Surg. 2004 Jan;30(1):63-6 [14692930.001]
  • [Cites] Transplantation. 2004 Jan 15;77(1):115-21 [14724445.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):116-20 [14732670.001]
  • [Cites] J Am Acad Dermatol. 2004 Mar;50(3):363-7 [14988676.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):337-40 [14996106.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):295-300 [15069697.001]
  • [Cites] Br J Dermatol. 2004 Jun;150(6):1061-9 [15214890.001]
  • [Cites] Australas J Dermatol. 2004 Aug;45(3):172-4 [15250896.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):196-200 [15270891.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Aug;5(4):397-408 [15320770.001]
  • [Cites] Br J Dermatol. 2004 Aug;151(2):472-80 [15327557.001]
  • [Cites] Onkologie. 2004 Aug;27(4):407-11 [15347900.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 May;130(5):279-84 [14997383.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):143-8 [2121931.001]
  • [Cites] Aust N Z J Surg. 1991 May;61(5):340-8 [2025186.001]
  • [Cites] Photochem Photobiol. 1991 Nov;54(5):659 [1798741.001]
  • [Cites] Photochem Photobiol. 1992 Jun;55(6):931-48 [1409894.001]
  • [Cites] Arch Dermatol Res. 1995;287(7):665-74 [8534131.001]
  • [Cites] J Urol. 1996 Jan;155(1):105-9; discussion 109-10 [7490803.001]
  • [Cites] Photochem Photobiol. 1996 Jun;63(6):892-7 [8992510.001]
  • [Cites] Dermatology. 1996;192(3):246-51 [8726640.001]
  • [Cites] J Photochem Photobiol B. 1996 Nov;36(2):169-74 [9002254.001]
  • [Cites] J Photochem Photobiol B. 1996 Nov;36(2):199-204 [9002261.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2282-308 [9191516.001]
  • [Cites] Arch Dermatol. 1997 Jun;133(6):727-32 [9197826.001]
  • [Cites] Photochem Photobiol. 1997 Oct;66(4):493-6 [9337620.001]
  • [Cites] Aesthetic Plast Surg. 1997 Nov-Dec;21(6):437-9 [9354609.001]
  • [Cites] Arch Dermatol. 1998 Feb;134(2):207-14 [9487213.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):746-51 [9579539.001]
  • [Cites] Australas J Dermatol. 1998 May;39(2):63-8; quiz 69-70 [9611372.001]
  • [Cites] J Clin Laser Med Surg. 1996 Oct;14(5):219-21 [9612186.001]
  • [Cites] Acta Derm Venereol. 1999 Jan;79(1):54-61 [10086861.001]
  • [Cites] Br J Dermatol. 1999 Mar;140(3):514-7 [10233277.001]
  • [Cites] J Invest Dermatol. 1959 Feb;32(2, Part 2):229-31 [13641790.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Jan 7;44(3):419-23 [15624158.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):13-8 [15672050.001]
  • [Cites] Breast. 2005 Feb;14(1):65-7 [15695084.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):765-72 [15840111.001]
  • [Cites] Br J Dermatol. 2000 Feb;142(2):338-9 [10730770.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):825-6 [10792247.001]
  • [Cites] Cancer. 2000 May 15;88(10):2275-82 [10820349.001]
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):396-401 [10951274.001]
  • [Cites] J Urol. 2006 Apr;175(4):1201-7 [16515960.001]
  • [Cites] Br J Dermatol. 2006 Apr;154(4):747-50 [16536822.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2006;25(1-2):441-51 [16566734.001]
  • [Cites] Acta Derm Venereol. 2006;86(1):25-8 [16585985.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):551-6 [16700893.001]
  • [Cites] Int J Dermatol. 2006 May;45(5):489-98 [16700779.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • (PMID = 21080805.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES016936-01A2; United States / NCI NIH HHS / CA / P30 CA014599; United States / NIEHS NIH HHS / ES / R01 ES016936; United States / Intramural NIH HHS / / ZIA ES050117-21; United States / NIEHS NIH HHS / ES / ES016936-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS263919; NLM/ PMC3030451
  •  go-up   go-down


51. Panizzon RG: [Dermatologic radiotherapy]. Hautarzt; 2007 Aug;58(8):701-10, quiz 711
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Another important parameter is the half-value depth which should correspond to the depth of the tumor below the skin surface.
  • In this way the skin is not over-exposed to radiation treatment.
  • Indications for radiotherapy of malignant skin tumors include basal cell carcinoma, squamous cell carcinoma, severe actinic keratoses, lentigo maligna, lentigo maligna melanoma, Merkel cell carcinoma, and Kaposi sarcoma, as well as T- and B-cell lymphomas.
  • Most patients with malignant skin tumors require life-long monitoring after radiotherapy.
  • [MeSH-major] Precancerous Conditions / radiotherapy. Skin Diseases / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Eczema / radiotherapy. Humans. Keloid / radiotherapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, T-Cell, Cutaneous / radiotherapy. Palliative Care. Psoriasis / radiotherapy. Radiotherapy Dosage. Sarcoma, Kaposi / radiotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639284.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


52. Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, Kwon P, Wetherill G, Curtin F, Menter A: A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology; 2006;213(3):204-14
MedlinePlus Health Information. consumer health - Psoriasis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Psoriasis is a chronic, incurable immune-mediated disease.
  • The results for the efalizumab-treated patients were compared with the data on psoriasis patients from insurance claims databases and a registry of events in the general population.
  • RESULTS: The efalizumab- and placebo-treated patients had similar incidence rates of malignancy, including lymphoproliferative disease, solid tumor, malignant melanoma and nonmelanoma skin cancer.
  • The incidence of nonmelanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma, in patients receiving efalizumab or placebo was elevated relative to the external databases.
  • The difference observed with nonmelanoma skin cancer may be due to biases introduced by the clinical trial methodology.
  • Additional patient observation is necessary to ascertain whether a link exists between efalizumab therapy and nonmelanoma skin cancer above that normally observed in psoriasis patients.

  • Genetic Alliance. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033169.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Comparative Study; Meta-Analysis
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / efalizumab
  •  go-up   go-down


53. Bäckvall H, Asplund A, Gustafsson A, Sivertsson A, Lundeberg J, Ponten F: Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. Mutat Res; 2005 Apr 1;571(1-2):65-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma.
  • Skin cancer provides an advantageous model for studying the development of cancer.
  • Detectable lesions occur early during tumor progression, facilitating molecular analysis of the cell populations from both preneoplastic and neoplastic lesions.
  • Alterations of the p53 tumor suppressor gene are very common in non-melanoma skin cancer, and dysregulation of p53 pathways appear to be an early event in the tumor development.
  • A high frequency of epidermal p53 clones has been detected in chronically sun-exposed skin.
  • The abundance of clones containing p53 mutated keratinocytes adjacent to basal cell (BCC) and squamous cell carcinoma (SCC) suggests a role in human skin carcinogenesis.
  • Microdissection-based studies have also shown that different parts of individual BCC tumors can share a common p53 mutation yet differ with respect to additional alterations within the p53 gene, consistent with subclonal development within tumors.
  • Here, we present examples of using well-defined cell populations, including single cells, from complex tissue in combination with molecular tools to reveal features involved in skin carcinogenesis.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Genetic Heterogeneity. Skin Neoplasms / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15748639.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 79
  •  go-up   go-down


54. Sharquie KE, Al-Meshhadani SA, Al-Nuaimy AA: Invasive squamous cell carcinoma of the eyes in patients with epidermodysplasia verruciformis. Saudi Med J; 2007 May;28(5):787-90
Genetic Alliance. consumer health - Epidermodysplasia Verruciformis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive squamous cell carcinoma of the eyes in patients with epidermodysplasia verruciformis.
  • They developed frequent multiple basal and squamous cell carcinoma, all of them had periorbital squamous cell carcinoma that invaded the orbit and ended with enucleation of their eyes.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Epidermodysplasia Verruciformis / complications. Orbital Neoplasms / complications
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / complications. Eye Enucleation. Humans. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17457453.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


55. Leibeling D, Laspe P, Emmert S: Nucleotide excision repair and cancer. J Mol Histol; 2006 Sep;37(5-7):225-38
MedlinePlus Health Information. consumer health - Hair Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NER consists of a multistep process in which the DNA lesion is recognized and demarcated by DNA unwinding.
  • XP patients show severe sun sensitivity, freckling in sun exposed skin, and develop skin cancers already during childhood.
  • Clinical symptoms of TTD patients include sun sensitivity, freckling in sun exposed skin areas, and brittle sulfur-deficient hair.
  • In contrast to XP patients, CS and TTD patients are not skin cancer prone.
  • Studying these syndromes can increase the knowledge of skin cancer development including cutaneous melanoma as well as basal and squamous cell carcinoma in general that may lead to new preventional and therapeutic anticancer strategies in the normal population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855787.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 150
  •  go-up   go-down


56. Russo GG: Actinic keratoses, basal cell carcinoma, and squamous cell carcinoma: uncommon treatments. Clin Dermatol; 2005 Nov-Dec;23(6):581-6
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses, basal cell carcinoma, and squamous cell carcinoma: uncommon treatments.
  • This contribution will discuss the treatment of actinic keratoses, basal cell carcinomas, and squamous cell carcinoma using methods that are not routinely established but have been used for a long period.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Keratosis / drug therapy. Photosensitivity Disorders / therapy. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. COLCHICINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325066.001).
  • [ISSN] 0738-081X
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 144O8QL0L1 / Diclofenac; 9004-61-9 / Hyaluronic Acid; SML2Y3J35T / Colchicine
  • [Number-of-references] 53
  •  go-up   go-down


57. Han A, Penrose C, Goldsmith A, Marmur ES: Case-based considerations in the treatment of actinic keratoses: utilizing combination or sequential therapy with 5-fluorouracil cream and destructive treatments. J Drugs Dermatol; 2010 Jul;9(7):864-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Actinic keratoses are premalignant lesions that increase in frequency with each decade of life and have the potential to progress to squamous cell carcinoma.
  • Non-melanoma skin cancers, such as squamous cell carcinoma and basal cell carcinoma, also represent sun-related conditions that require early and aggressive treatment.
  • The following case-based review represents typical situations where multiple treatments were combined to manage actinic keratosis, squamous cell carcinoma and basal cell carcinoma in patients over an extended treatment period.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Fluorouracil / administration & dosage. Keratosis, Actinic / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Cryotherapy. Female. Humans. Male. Middle Aged. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677546.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


58. Watkins J: Dermatology and the community nurse: actinic (solar) keratosis. Br J Community Nurs; 2010 Jan;15(1):6, 8, 10-1
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are then able to check other sun-exposed areas such as the face, ears, scalp, back and limbs to discover any other lesions or more serious problems of basal cell carcinoma, squamous cell carcinoma or malignant melanoma the would require referral, sometimes urgently, to a dermatologist for full assessment and treatment.
  • [MeSH-major] Keratosis / nursing. Skin Neoplasms / nursing. Sunlight / adverse effects
  • [MeSH-minor] Community Health Nursing. Diagnosis, Differential. Humans. Nursing Diagnosis. Protective Clothing. Risk Factors. Sunscreening Agents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216512.001).
  • [ISSN] 1462-4753
  • [Journal-full-title] British journal of community nursing
  • [ISO-abbreviation] Br J Community Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sunscreening Agents
  • [Number-of-references] 13
  •  go-up   go-down


59. Stranahan D, Cherpelis BS, Glass LF, Ladd S, Fenske NA: Immunohistochemical stains in Mohs surgery: a review. Dermatol Surg; 2009 Jul;35(7):1023-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: During Mohs surgery, there are instances in which residual tumor cells may be difficult to detect, thereby increasing the risk of incomplete excision and tumor recurrence.
  • RESULTS: Various immunostains have proved useful in detecting tumor cells in various malignancies, including melanoma, basal cell carcinoma, squamous cell carcinoma, dermatofibrosarcoma protuberans, extramammary Paget's disease, primary cutaneous mucinous carcinoma, granular cell tumor, and trichilemmal carcinoma.
  • CONCLUSIONS: In this article, we review immunohistochemical stains that have been employed in Mohs micrographic surgery and evaluate their utility in enhancing detection of residual tumors with respect to tumor type, particularly in situations in which detection of residual tumor may be difficult.
  • [MeSH-major] Coloring Agents. Immunohistochemistry / methods. Mohs Surgery. Neoplasm, Residual / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19397647.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Coloring Agents
  • [Number-of-references] 45
  •  go-up   go-down


60. Perrem K, Lynch A, Al Nooh F, Leader M, Elaine Kay: The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population. Hum Pathol; 2008 Jul;39(7):1034-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population.
  • Renal transplant recipients incur markedly higher rates of nonmelanoma skin cancer, including both basal and squamous cell carcinoma, by unknown mechanisms that are thought to be activated by long-term immunosuppression.
  • These tumors typically arise in sun-exposed areas of the skin and are biologically more aggressive in renal transplant recipients compared with nontransplant patients.
  • Interestingly also, the incidence of squamous cell carcinoma is generally 2- to 3-fold higher than that of basal cell carcinoma in renal transplant recipients, which is a reversal of the trend in the nontransplant population.
  • We have shown in a previous report that the increased incidence of squamous cell carcinoma in renal transplant patients is characterized by increased telomere lengths when compared with the same tumors in the nontransplant population.
  • In our current study, we performed a similar analysis of a cohort of 35 basal cell carcinoma samples from both the renal transplant and nontransplant patient groups.
  • We find that, in contrast to the situation in squamous cell carcinoma, the telomeres of the basal cell carcinomas in renal transplant recipients are in fact shorter than their counterparts in the nontransplant population, but also that these lengths are considerably longer in both cases than their squamous cell counterparts.
  • This is the first report to comprehensively show that the telomere lengths significantly differ between basal and squamous cell carcinomas.
  • These data also suggest that future treatment strategies for nonmelanoma skin cancers that are based upon telomerase inhibition, including those arising in transplant patients, may require different approaches for these two different skin lesions.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Kidney Transplantation. Skin Neoplasms / pathology. Telomere / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Humans. Immunocompromised Host. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18482746.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Wilkins K, Dolev JC, Turner R, LeBoit PE, Berger TG, Maurer TA: Approach to the treatment of cutaneous malignancy in HIV-infected patients. Dermatol Ther; 2005 Jan-Feb;18(1):77-86
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients infected with human immunodeficiency virus (HIV) have an increased risk of developing skin cancers.
  • This article will review and discuss management issues for the following malignancies: lymphomas, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, and Kaposi's sarcoma.
  • [MeSH-major] HIV Infections / complications. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Humans. Lymphoma / complications. Lymphoma / diagnosis. Lymphoma / therapy. Melanoma / complications. Melanoma / diagnosis. Melanoma / therapy. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / therapy

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842615.001).
  • [ISSN] 1396-0296
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 148
  •  go-up   go-down


62. Snarskaia ES, Molochkov VA, Frank GA, Zavalishina LA: [Matrix metalloproteinases and their tissue inhibitors in basal cell and metatypical cancer of the skin]. Arkh Patol; 2005 May-Jun;67(3):14-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Matrix metalloproteinases and their tissue inhibitors in basal cell and metatypical cancer of the skin].
  • 10 cases of ulcerative-nodular basal cell carcinoma and 10 cases of metatypical carcinoma of the skin were studied immunohistochemically for immunoexpression of matrix metalloproteinases (MMP-1, MMP-9) and their endogenic tissue inhibitors (TIMP-1, TIMP-2) in combination with PCNA, p53 tumor complexes.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Matrix Metalloproteinase 1 / analysis. Matrix Metalloproteinase 9 / analysis. Skin Neoplasms / diagnosis. Tissue Inhibitor of Metalloproteinases / analysis
  • [MeSH-minor] Diagnosis, Differential. Humans. Proliferating Cell Nuclear Antigen / analysis. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16075605.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tissue Inhibitor of Metalloproteinases; 0 / Tumor Suppressor Protein p53; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


63. Vasconcelos HM Jr, Almeida AL, Sagawa A, Carvalho RM, Avila MP: [An advanced case of basosquamous carcinoma of the orbit: case report]. Arq Bras Oftalmol; 2009 Nov-Dec;72(6):819-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An advanced case of basosquamous carcinoma of the orbit: case report].
  • [Transliterated title] Carcinoma basoescamoso avançado de órbita: relato de caso.
  • Basosquamous carcinoma is a rare tumor with features of both basal cell and squamous cell carcinoma, linked by a transition area.
  • It is a rare epithelial neoplasm with a tendency for local recurrence.
  • It also has a high incidence of distant metastasis, a condition that differentiates it from the basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Orbital Neoplasms / pathology. Patient Compliance
  • [MeSH-minor] Disease Progression. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098906.001).
  • [ISSN] 1678-2925
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


64. Ezzedine K, Latreille J, Kesse-Guyot E, Galan P, Hercberg S, Guinot C, Malvy D: Incidence of skin cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation. Eur J Cancer; 2010 Dec;46(18):3316-22
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of skin cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation.
  • CONTEXT: In the SU.VI.MAX study, antioxidant supplementation for 7.5 years was found to increase skin cancer risk in women but not in men.
  • OBJECTIVE: To investigate the potential residual or delayed effect of antioxidant supplementation on skin cancer incidence after a 5-year post-intervention follow-up.
  • DESIGN, SETTING AND PARTICIPANTS: Assessment of skin cancer including melanoma and non-melanoma during the post-intervention follow-up (September 2002-August 2007).
  • MAIN OUTCOME MEASURES: Total skin cancer incidence, including melanoma, squamous cell carcinoma and basal cell carcinoma.
  • Six squamous cell carcinomas were found in women and 15 in men (10 and 25, respectively, for the total period).
  • Finally, 40 basal cell carcinomas appeared in women and 36 in men (98 and 94, respectively, for the total period).
  • No delayed effects, either on melanoma or non-melanoma skin cancers, were observed for either gender.
  • CONCLUSIONS: The risk of skin cancers associated with antioxidant intake declines following interruption of supplementation.
  • This supports a causative role for antioxidants in the evolution of skin cancers.
  • [MeSH-major] Antioxidants / adverse effects. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology. Vitamins / adverse effects

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20605091.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00272428
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Vitamins
  •  go-up   go-down


65. Moscarelli L, Zanazzi M, Mancini G, Rossi E, Caroti L, Rosso G, Bertoni E, Salvadori M: Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients. Clin Nephrol; 2010 Jun;73(6):439-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Skin cancer (SC) is the most frequent malignancy after renal transplantation (RT), especially squamous and basal cell carcinoma.
  • The observation that angiotensin II is a potent angiogenic and growth factor raises the possibility that blocking its effects could reduce the incidence of skin cancer.
  • OBJECTIVES: To evaluate the incidence of keratinocyte cancer in RT recipients, the timing of occurrence of the skin events after RT; to compare the incidence of SC in our RT recipients and in RT patients on angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers therapy (ARBs) and their combination.
  • BCC was the most frequent type of keratinocyte cancer in non users and in users.
  • No association with incidence of BCC or SCC was observed for other classes of antihypertensive drugs (calcium antagonists, beta-blockers, alpha-blockers).
  • [MeSH-major] Angiotensin Receptor Antagonists. Angiotensin-Converting Enzyme Inhibitors / administration & dosage. Kidney Transplantation. Receptors, Angiotensin / therapeutic use. Skin Neoplasms / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / prevention & control. Female. Humans. Male. Middle Aged. Postoperative Complications. Risk Factors


66. Sengupta SR, Das NK, Datta PK: Pathogenesis, clinical features and pathology of chronic arsenicosis. Indian J Dermatol Venereol Leprol; 2008 Nov-Dec;74(6):559-70
Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenicosis is a multisystem disorder, with virtually no system spared from its vicious claw; though its predominant manifestations are linked to cutaneous involvement.
  • Cutaneous effects take the form of pigmentary changes, hyperkeratosis, and skin cancers (Bowen's disease, squamous cell carcinoma, and basal cell epithelioma).
  • Peripheral vascular disease (blackfoot disease), hypertension, ischemic heart disease, noncirrhotic portal hypertension, hepatomegaly, peripheral neuropathy, respiratory and renal involvement, bad obstetrical outcome, hematological disturbances, and diabetes mellitus are among the other clinical features linked to arsenic toxicity.
  • Understandably the detoxification/bio-inactivation process is not a complete defense against the vicious metalloid, and it can cause chromosomal aberration, impairment of DNA repair process, alteration in the activity of tumor suppressor gene, etc., leading to genotoxicity and carcinogenicity.
  • Increased expression of cytokeratins, keratin-16 (marker for hyperproliferation) and keratin-8 and -18 (marker for less differentiated epithelial cells), can be related to the histopathological findings of hyperkeratosis and dysplastic cells in the arsenicosis skin lesion.
  • [MeSH-major] Arsenic Poisoning / epidemiology. Arsenic Poisoning / pathology. Skin Diseases / epidemiology. Skin Diseases / pathology
  • [MeSH-minor] Animals. Arsenic / adverse effects. Chronic Disease. Environmental Exposure / adverse effects. Humans. Water Pollutants / adverse effects. World Health Organization

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19171978.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Water Pollutants; N712M78A8G / Arsenic
  • [Number-of-references] 115
  •  go-up   go-down


67. Qureshi AA, Laden F, Colditz GA, Hunter DJ: Geographic variation and risk of skin cancer in US women. Differences between melanoma, squamous cell carcinoma, and basal cell carcinoma. Arch Intern Med; 2008 Mar 10;168(5):501-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geographic variation and risk of skin cancer in US women. Differences between melanoma, squamous cell carcinoma, and basal cell carcinoma.
  • BACKGROUND: Occurrences of melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) have been associated with varying geography.
  • Our goal was to evaluate differences in risk of these skin cancers according to residence at varying UV indices at 3 time points.
  • The outcome measure was diagnosis of melanoma, SCC, or BCC.
  • RESULTS: During the 18-year study, 420 cases of melanoma, 863 cases of SCC, and 8215 cases of BCC occurred.
  • Although elevated, the age-adjusted risk of BCC at 30 years of age associated with residence in these states was substantially less.
  • CONCLUSIONS: The risk of SCC is independently affected by residence in locations with medium and high UV indices; the gradient of risk is weaker for BCC; and the risk of melanoma does not change significantly across this gradient.


68. Altan-Yaycioglu R, Canan H, Sizmaz S, Bal N, Pelit A, Akova YA: Nasolacrimal duct obstruction: clinicopathologic analysis of 205 cases. Orbit; 2010 Oct;29(5):254-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only one patient had the diagnosis of chronic leukemia, others had no preexisting history of systemic disease.
  • Three patients had abnormal pathology: Lymphoproliferative disease in the patient with chronic leukemia, granulomatous inflammation, and basosquamous cell carcinoma.
  • Even though rare, malignant or systemic disease in patients with neither specific history nor clinical or radiological finding might be observed in these cases.
  • Thus, we recommend taking biopsy if any suspicion of abnormality of the lacrimal sac exists.
  • [MeSH-major] Lacrimal Duct Obstruction / diagnosis. Nasolacrimal Duct / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Child. Dacryocystorhinostomy. Female. Humans. Lacrimal Apparatus Diseases / diagnosis. Male. Middle Aged. Prospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20704489.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Gurses I, Doganay S, Mizrak B: Expression of glucose transporter protein-1 (Glut-1) in ocular surface squamous neoplasia. Cornea; 2007 Aug;26(7):826-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of glucose transporter protein-1 (Glut-1) in ocular surface squamous neoplasia.
  • PURPOSE: To examine the expression of glucose transporter protein-1 (GLUT-1) in ocular surface squamous neoplasia and to study its relationship with degree of neoplasia and cell proliferation index (Ki-67 labeling index).
  • METHODS: Twelve cases diagnosed as ocular surface squamous neoplasia (4 invasive and 8 intraepithelial tumors) at Inonu University Faculty of Medicine, Department of Pathology, were included in this study.
  • There were 3 squamous cell carcinomas, 1 basosquamous cell carcinoma, and 8 conjunctival intraepithelial neoplasms.
  • GLUT-1 immunostaining was observed in all layers of the neoplastic epithelium of squamous cell carcinoma.
  • Intense staining for GLUT-1 was determined in the upper two thirds of the severe dysplastic squamous epithelium.
  • CONCLUSIONS: Marked GLUT-1 and Ki-67 immunoreactive cells throughout the neoplastic epithelium of ocular surface squamous neoplasia were observed.
  • [MeSH-major] Carcinoma in Situ / metabolism. Carcinoma, Basosquamous / metabolism. Carcinoma, Squamous Cell / metabolism. Conjunctival Neoplasms / metabolism. Corneal Diseases / metabolism. Glucose Transporter Type 1 / metabolism

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667617.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Ki-67 Antigen; IY9XDZ35W2 / Glucose
  •  go-up   go-down


70. Massari LP, Kastelan M, Gruber F: Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis. Coll Antropol; 2007 Jan;31 Suppl 1:83-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis.
  • Basal cell carcinoma and squamous cell carcinoma, collectively termed non-melanoma skin cancers are the most common malignant tumors in humans.
  • Basal cell carcinoma grows slowly and metastatic spread is very rare.
  • Squamous cell carcinoma is characterized by infiltrative, destructive growth and metastasis.
  • Long-term exposure of skin to UV light has a great impact on development of these epidermal malignancies.
  • The major role in development of skin cancer is given to proapoptotic p53 molecule or tumor suppressor gene which mutation due to UV exposure leads to resistance of DNA-damaged cell to apoptosis.
  • Other proapoptotic molecules such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) are strongly expressed in basal cell carcinoma and squamous cell carcinoma that could be explained by the ability of tumor to escape the attack of immune system.
  • [MeSH-major] Apoptosis. Carcinoma, Basal Cell / physiopathology. Carcinoma, Squamous Cell / physiopathology. Neoplasms, Radiation-Induced / physiopathology. Skin Neoplasms / physiopathology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17469758.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 29
  •  go-up   go-down


71. Papadopoulos O, Konofaos P, Chrisostomidis C, Georgiou P, Frangoulis M, Champsas G, Betsi E, Zapantis-Fragos M: Orbitopalpebral repair after 835 excisions of malignant tumours. Scand J Plast Reconstr Surg Hand Surg; 2005;39(6):353-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbitopalpebral repair after 835 excisions of malignant tumours.
  • Basal cell carcinoma (BCC) is the most common malignant tumour of the eyelids, and squamous cell carcinoma (SCC), mixed carcinomas or basosquamous cell carcinomas (BSC), and cutaneous melanomas (CM), also invade the eyelids and periocular zones.
  • The purpose of this study was to document various, simple or complex reconstructive procedures that may be used after excision of malignant tumours of the eyelids and to assess the outcome of surgical treatment.

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16298808.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Chovanec M, Smetana K Jr, Plzák J, Betka J, Plzáková Z, Stork J, Hrdlicková E, Kuwabara I, Dvoránková B, Liu FT, Kaltner H, André S, Gabius HJ: Detection of new diagnostic markers in pathology by focus on growth-regulatory endogenous lectins. The case study of galectin-7 in squamous epithelia. Prague Med Rep; 2005;106(2):209-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of new diagnostic markers in pathology by focus on growth-regulatory endogenous lectins. The case study of galectin-7 in squamous epithelia.
  • Lectins represent one of pivotal regulators of the cell proliferation The potential of galectin-7 as a new prognostic marker was studied in normal and transformed squamous epithelia of both ectodermal (epidermis, cornea vs. trichoepithelioma, basal and squamous cell carcinoma) and endodermal (vocal fold epithelium vs. carcinoma) origin.
  • Its expression is significantly reduced in malignant cells, thus galectin-7 might be a differentiation marker of epithelial malignancies.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Epithelium / chemistry. Galectins / analysis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Division / physiology. Cells, Cultured. Humans. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315769.001).
  • [ISSN] 1214-6994
  • [Journal-full-title] Prague medical report
  • [ISO-abbreviation] Prague Med Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectins; 0 / LGALS7 protein, human
  •  go-up   go-down


73. Kim GK, Del Rosso JQ, Bellew S: Skin cancer in asians: part 1: nonmelanoma skin cancer. J Clin Aesthet Dermatol; 2009 Aug;2(8):39-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer in asians: part 1: nonmelanoma skin cancer.
  • Since the 1960s, basal cell carcinoma and squamous cell carcinoma among the Caucasian population have increased 3 to 8 percent annually.
  • Although Asians display relative protection from basal cell carcinoma and squamous cell carcinoma, incidence rates of these nonmelanoma skin cancers have been increasing over the past three decades.
  • With changing demographics and a steady rise in the minority population in the United States, there is an increased need for further studies of cutaneous malignancies within Asian and other ethnic populations.
  • This article reviews nonmelanoma skin cancers in the Asian population with an insight into contributing factors, such as skin type, occupation, cultural practices, and genetic components.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photochem Photobiol. 2008 Jan-Feb;84(1):63-6 [18173702.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5):741-60; quiz 761-4 [17052479.001]
  • [Cites] Photochem Photobiol Sci. 2006 Feb;5(2):208-14 [16465307.001]
  • [Cites] Ann Surg. 1965 Feb;161:170-88 [14260013.001]
  • [Cites] Med Oncol. 1999 Jul;16(2):86-94 [10456656.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):843-4 [10411160.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):413-21 [2212139.001]
  • [Cites] Arch Dermatol. 1988 Jun;124(6):869-71 [3377516.001]
  • [Cites] J Dermatol. 1984 Aug;11(4):313-21 [6392379.001]
  • [Cites] J Dermatol. 1990 Jun;17(6):342-6 [2384636.001]
  • [Cites] Plast Reconstr Surg. 1978 Sep;62(3):407-14 [693668.001]
  • [Cites] Ann Dermatol Venereol. 2003 Apr;130(4):413-6 [12843850.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):841-8 [11298546.001]
  • [Cites] J Epidemiol. 1999 Dec;9(6 Suppl):S14-21 [10709346.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):781-6 [10411152.001]
  • [Cites] J Dermatol Sci. 1999 Apr;19(3):161-5 [10215187.001]
  • [Cites] J Dermatol Sci. 1997 Nov;16(1):74-8 [9438911.001]
  • [Cites] J Dermatol Sci. 1997 Sep;15(3):183-7 [9302646.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 1996 Feb;12(1):22-6 [8884895.001]
  • [Cites] J Trauma. 1997 Jan;42(1):104-7 [9003266.001]
  • [Cites] Am J Dermatopathol. 2006 Dec;28(6):472-7 [17122490.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):124-30 [8606543.001]
  • [Cites] Dermatol Surg. 1996 Mar;22(3):217-26 [8599733.001]
  • [Cites] Dermatol Clin. 1995 Jul;13(3):583-94 [7554506.001]
  • [Cites] J Invest Dermatol. 1994 Apr;102(4):440-4 [8151121.001]
  • [Cites] Recent Results Cancer Res. 1995;139:263-73 [7597297.001]
  • [Cites] Int J Cancer. 1993 Apr 1;53(6):886-91 [8473047.001]
  • [Cites] Am J Epidemiol. 1996 Dec 1;144(11):1034-40 [8942434.001]
  • (PMID = 20729955.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2923966
  •  go-up   go-down


74. Terziqi H, Tarpila E: Reconstruction of large defect of lower lip and commissure using Karapandzic flap: case report. Niger J Med; 2009 Apr-Jun;18(2):222-3
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Xeroderma Pigmentosum (XP) is a photosensitive skin disease with a high risk for developing skin malignancy.
  • We present an 18-years-old boy with XP and recurrent basal and squamous cell carcinoma of lower lip.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Lip Neoplasms / surgery. Reconstructive Surgical Procedures. Surgical Flaps. Xeroderma Pigmentosum / pathology
  • [MeSH-minor] Adolescent. Humans. Male. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19630336.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


75. Chen T, Bertenthal D, Sahay A, Sen S, Chren MM: Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Arch Dermatol; 2007 Nov;143(11):1386-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma.
  • OBJECTIVE: To identify predictors of skin-related quality of life (QOL) after treatment of nonmelanoma skin cancer (NMSC).
  • SETTING: University-affiliated private practice and a Veterans Affairs clinic.
  • MAIN OUTCOME MEASURE: Skin-related QOL, measured with the 16-item version of Skindex-16, a validated measure.
  • RESULTS: Controlling for treatment group, the strongest independent predictor of skin-related QOL after treatment of NMSC was pretreatment skin-related QOL.
  • No tumor or care characteristic (including location of tumor, size of tumor, site of therapy, or training level of treating clinician [attending physician, resident, or nurse practitioner]) was found to predict better skin-related QOL after treatment of NMSC.
  • CONCLUSIONS: Patients with better pretreatment skin-related QOL, less comorbidity, and better mental health status had better skin-related QOL after treatment of NMSC.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Quality of Life. Skin / physiopathology. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2007 Nov;143(11):1429-32 [18025368.001]
  • [ErratumIn] Arch Dermatol. 2008 Feb;144(2):230
  • (PMID = 18025362.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K02 AR02203; United States / NIAMS NIH HHS / AR / K24-AR052667
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


76. Askari SK, Schram SE, Wenner RA, Bowers S, Liu A, Bangerter AK, Warshaw EM: Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven melanoma, basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an elderly male population. J Am Acad Dermatol; 2007 May;56(5):739-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven melanoma, basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an elderly male population.
  • BACKGROUND: Presenting signs/symptoms of skin cancer may aid in earlier detection and diagnosis.
  • OBJECTIVE: We sought to compare prospectively collected, presenting signs/symptoms of malignant melanoma (MM), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and seborrheic keratosis (SK).
  • METHODS: This analysis was part of a larger study on teledermatology involving 3039 skin neoplasms in 2152 patients at a Department of Veterans Affairs medical center.
  • At presentation, participants were asked about signs/symptoms of specific skin lesions.
  • In all, 912 biopsy-proven MM (39), BCC (411), SCC (238), and SK (224) were included in this analysis.
  • RESULTS: "No symptoms" was reported more often with MM (82%) as compared with BCC (relative risk [RR] 2.26, confidence interval [CI] 1.86, 2.75), SCC (RR 3.31, CI 2.54, 4.32), or SK (RR 2.0, CI 1.61, 2.48; all P < .0001).
  • Tenderness was more commonly reported with SCC (40%) as compared with MM (RR 15.9, CI 2.28, 110.69), SK (RR 3.0, CI 2.11, 4.39), or BCC (RR 2.6, CI 1.97, 3.38; all P < .0001).
  • Bleeding was more commonly reported with BCC (37%) as compared with SK (RR 2.3, CI 1.67, 3.20), SCC (RR 1.6, CI 1.22, 2.05), or MM (RR 29.8, CI 1.89, 469.65; all P <or= .007).
  • CONCLUSION: This study describes common signs/symptoms of BCC, SCC, and SK.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Keratosis, Seborrheic / diagnosis. Melanoma / diagnosis. Skin Diseases / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Humans. Male. Middle Aged. Prospective Studies. Skin Neoplasms / diagnosis


77. Eide MJ, Weinstock MA, Dufresne RG Jr, Neelagaru S, Risica P, Burkholder GJ, Upegui D, Phillips KA, Armstrong BK, Robinson-Bostom L: Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin). J Invest Dermatol; 2005 Feb;124(2):308-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin).
  • Larger keratinocyte carcinoma (KC) lesions are associated with higher morbidity.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2001 May;37(7):843-8 [11313171.001]
  • [Cites] Br J Dermatol. 2001 Mar;144(3):476-83 [11260002.001]
  • [Cites] Dermatol Surg. 2001 Nov;27(11):955-9 [11737130.001]
  • [Cites] Br J Dermatol. 2002 Jul;147(1):48-54 [12100184.001]
  • [Cites] Arch Dermatol. 2002 Aug;138(8):1043-51 [12164742.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):389-94 [12170189.001]
  • [Cites] Ann Plast Surg. 2002 Oct;49(4):439-42 [12370654.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]
  • [Cites] Br J Psychiatry. 1967 Jan;113(494):89-93 [6029373.001]
  • [Cites] J Dermatol Surg Oncol. 1981 Apr;7(4):311-6 [7240532.001]
  • [Cites] Prog Clin Biol Res. 1984;156:169-79 [6473424.001]
  • [Cites] J Psychosom Res. 1985;29(2):139-53 [4009515.001]
  • [Cites] J Am Acad Dermatol. 1988 Mar;18(3):591-8 [3351022.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] Eur J Surg Oncol. 1989 Apr;15(2):143-8 [2703058.001]
  • [Cites] Arch Dermatol. 1991 Mar;127(3):356-61 [1998366.001]
  • [Cites] J Am Acad Dermatol. 1991 Jan;24(1):1-13 [1999506.001]
  • [Cites] Postgrad Med. 1991 Mar;89(4):151-2, 155-8 [2000349.001]
  • [Cites] Ann R Coll Surg Engl. 1991 Jul;73(4):248-52 [1863047.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Sep;17(9):713-8 [1890243.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):2064-8 [1913555.001]
  • [Cites] Dermatol Surg. 1996 Mar;22(3):255-61 [8599737.001]
  • [Cites] J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):422-9 [9308558.001]
  • [Cites] Arch Dermatol. 1999 Mar;135(3):269-74 [10086447.001]
  • [Cites] Arch Dermatol. 1999 Mar;135(3):339-40 [10086457.001]
  • [Cites] J Clin Epidemiol. 1999 Nov;52(11):1111-6 [10527006.001]
  • [Cites] Br J Dermatol. 1999 Nov;141(5):783-7 [10583157.001]
  • [Cites] Br J Dermatol. 1999 Nov;141(5):876-9 [10583170.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):271-9 [10861504.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):280-5 [10861505.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1055-8 [11493098.001]
  • (PMID = 15675948.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / K24 MH063975; United States / NCI NIH HHS / CA / R01 CA078800; United States / AHRQ HHS / HS / T32 HS000011; United States / NCI NIH HHS / CA / CA 78800
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS12744; NLM/ PMC1613794
  •  go-up   go-down


78. Honeycutt KA, Waikel RL, Koster MI, Wang XJ, Roop DR: The effect of c-myc on stem cell fate influences skin tumor phenotype. Mol Carcinog; 2010 Apr;49(4):315-9
Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of c-myc on stem cell fate influences skin tumor phenotype.
  • Nonmelanoma skin cancers (NMSCs) consist of a variety of tumor types including basal cell carcinoma, squamous cell carcinoma, a variety of hair follicle tumors, and sebaceous gland tumors.
  • Our goal in the current study was to determine if alterations in the commitment of multipotent stem cells to different cell fates would influence tumor phenotype.
  • [MeSH-major] Proto-Oncogene Proteins c-myc / genetics. Skin Neoplasms / genetics. Skin Neoplasms / pathology. Stem Cells / pathology
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Adenocarcinoma, Sebaceous / pathology. Animals. Carcinogens / toxicity. Cell Differentiation / genetics. Cell Lineage / genetics. Crosses, Genetic. Female. Heterozygote. Male. Mice. Mice, Inbred ICR. Mice, Inbred Strains. Mice, Transgenic. Multipotent Stem Cells / pathology. Papilloma / pathology. Phenotype. Sebaceous Gland Neoplasms / pathology. Tetradecanoylphorbol Acetate / pharmacology. Transgenes

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146250.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR47898; United States / NCI NIH HHS / CA / CA09197; United States / NCI NIH HHS / CA / CA105491; United States / NCI NIH HHS / CA / CA52607; United States / NCI NIH HHS / CA / CA79998
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Proto-Oncogene Proteins c-myc; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


79. Maroldi R, Farina D, Borghesi A, Marconi A, Gatti E: Perineural tumor spread. Neuroimaging Clin N Am; 2008 May;18(2):413-29, xi
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineural tumor spread.
  • Perineural spread (PNS) refers to the extent of tumor cells or other nonneoplastic lesions along the tissues of the nerve sheath, its overall incidence ranges from 2.5% to 5%.
  • PNS is more frequently associated with carcinoma arising from minor or major salivary glands (more often adenoid cystic carcinoma), mucosal or cutaneous squamous cell carcinoma, basal cell carcinoma, melanoma, lymphoma, and sarcoma.
  • Therefore, radiologists must be aware of the relevant cranial nerve anatomy and thoroughly scrutinize not only the nerves close to the primary tumor site but also the whole neural pathways that can be accessed by PNS.
  • Equally critical is knowledge of the radiologic appearance of perineural tumor extension and the best imaging strategies to detect PNS.
  • [MeSH-major] Cranial Nerve Neoplasms / diagnosis. Cranial Nerve Neoplasms / secondary. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466839.001).
  • [ISSN] 1052-5149
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


80. Hatina J, Ruzicka T: [Relevance of cell culture models in cutaneous tumour biology. Part I: tumour cell lines]. Hautarzt; 2008 Jan;59(1):36-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relevance of cell culture models in cutaneous tumour biology. Part I: tumour cell lines].
  • [Transliterated title] Stellenwert der Zellkulturmodelle in kutaner Tumorbiologie. Teil I: Zelllinien tumorigen transformierter Zellen.
  • Cutaneous squamous cell carcinoma, basal cell carcinoma and melanoma, much like all other human solid tumors, result from a multi-step process in which genetic and epigenetic changes accumulate in the affected cells.
  • Cell culture models are a very valuable experimental system.
  • Tumor cell lines display similar functional hierarchy as tumors or tissues in vivo and can, consequently, provide a crucial source of minor cell subsets, like tumor stem cells.
  • Progression series of clonally related cell lines offer the opportunity to follow the process of sequential acquisition of transformation-related traits up to the development of properties with direct clinical equivalents, like tumorigenicity and metastatic competence.
  • While for most studies, human transformed cell lines are the model of choice, there are questions for which animal cell lines are strongly preferred, such as interactions between the tumor and the immune system.
  • To properly interpret the results of all experiments with classical two-dimensional cell culture, a possible danger of artifacts due to grossly unnatural environment must be constantly taken into account.
  • [MeSH-major] Cell Line, Tumor / pathology. Cell Line, Tumor / physiology. Disease Models, Animal. Skin Neoplasms / pathology. Skin Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Jan 8;23(1):30-8 [14712208.001]
  • [Cites] Annu Rev Pathol. 2007;2:175-89 [18039097.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):441-52 [10433937.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):159-67 [10623663.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;995:151-61 [12814947.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 15;142(2):87-91 [12699882.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7147-57 [14612508.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4359-70 [9494534.001]
  • [Cites] Mol Carcinog. 1998 Nov;23(3):144-58 [9833775.001]
  • [Cites] J Surg Res. 1995 Feb;58(2):165-74 [7861768.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3075-86 [8674065.001]
  • [Cites] Cancer Res. 1990 Apr 15;50(8):2296-302 [2156614.001]
  • [Cites] J Cell Biochem. 1994 Feb;54(2):161-73 [8175891.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Exp Dermatol. 2007 Apr;16(4):297-301 [17359335.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):365-78 [14973382.001]
  • [Cites] Exp Dermatol. 2000 Apr;9(2):104-17 [10772384.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1567-79 [11583982.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:339-73 [16824012.001]
  • [Cites] Arch Dermatol. 1996 Oct;132(10):1185-93 [8859029.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1372-7 [16470173.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4320-33 [15899824.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):1026-36 [12821146.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5670-6 [4053039.001]
  • [Cites] J Invest Dermatol. 2005 Feb;124(2):401-4 [15675960.001]
  • [Cites] Exp Cell Res. 2000 Aug 1;258(2):352-60 [10896786.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):935-46 [17320377.001]
  • [Cites] J Dtsch Dermatol Ges. 2005 Jul;3(7):493-503 [15967008.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2205-11 [2009539.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2840-7 [2183932.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):875-9 [8631027.001]
  • [Cites] Dtsch Med Wochenschr. 2007 Aug;132(31-32):1629-32 [17654417.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1214-6 [16702970.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3759-65 [12097286.001]
  • [Cites] Cancer Res. 1980 May;40(5):1636-44 [7370995.001]
  • [Cites] Histol Histopathol. 2002;17 (3):951-9 [12168807.001]
  • [Cites] J Invest Dermatol. 2000 Dec;115(6):1095-103 [11121147.001]
  • [Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S35-42 [9578415.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3837-44 [12881305.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] J Invest Dermatol. 2005 Feb;124(2):457-65 [15675968.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3112-7 [8674069.001]
  • [Cites] Prostate. 1986;9(3):261-81 [3774632.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5 [9448283.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5270-82 [15289333.001]
  • [Cites] Schweiz Med Wochenschr. 2000 Apr 29;130(17):617-24 [10829299.001]
  • [Cites] Hautarzt. 2004 Oct;55(10):942-51 [15349693.001]
  • [Cites] Pathologe. 1994 Jun;15(3):141-9 [8072948.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):976-81 [12439909.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):668-75 [7532159.001]
  • [Cites] Nat Med. 1997 Jul;3(7):788-92 [9212109.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • (PMID = 18058078.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 64
  •  go-up   go-down


81. Yenidunya MO, Demirseren ME, Ceran C: Bilobed flap reconstruction in infraorbital skin defects. Plast Reconstr Surg; 2007 Jan;119(1):145-50
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilobed flap reconstruction in infraorbital skin defects.
  • Improper closure of skin defects involving this region may lead to deformity in the lower lid and to ectropion.
  • This report presents the authors' experience with 15 patients who had infraorbital skin defects reconstructed with the bilobed flap from the zygomatic and lateral cheek regions.
  • Pathologic diagnoses included basal cell carcinoma, squamous cell carcinoma, melanoma, and hemangioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255668.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Thomas L, Dalle S: [Pathology of the eyelid in elderly patients]. J Fr Ophtalmol; 2006 Jun;29(6):672-86
MedlinePlus Health Information. consumer health - Eyelid Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Illustrated review centered on diagnosis of the usual aspects and pitfalls of eyelid pathology divided into semiological chapters (tumors, blisters, erythema, etc.).
  • It is mainly centered on skin cancers (basal cell carcinoma, squamous cell carcinoma, adnexal carcinomas, and melanoma).
  • A number of rare diseases deserve mention since their presence could lead to the diagnosis of internal or systemic diseases (dermatomyositis, necrobiotic xanthogranuloma, Erdheim-Chester, etc.).
  • In such conditions, early diagnosis is often based on the observation of isolated periocular symptoms.
  • CONCLUSIONS: Even though topographic dermatology is a somewhat reductive vision of skin diseases, pathology of the eyelids deserves special mention because of its polymorphism as well as its diagnostic and/or therapeutic significance.
  • [MeSH-major] Eyelid Diseases / diagnosis
  • [MeSH-minor] Aged. Eyelid Neoplasms / diagnosis. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885900.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 123
  •  go-up   go-down


83. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST: Mast cells and cutaneous malignancies. Mod Pathol; 2006 Jan;19(1):149-59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper reviews the role of mast cells in the development and progression of basal cell carcinoma, squamous cell carcinoma and malignant melanoma.
  • Upon irradiation of the skin, trans-urocanic acid in the epidermis isomerizes to cis-urocanic acid, which stimulates neuropeptide release from neural c-fibers.
  • These neuropeptides in turn trigger histamine secretion from mast cells, leading to suppression of the cellular immune system. (2) Angiogenesis: Mast cells are the major source of vascular endothelial growth factor in basal cell carcinoma and malignant melanoma.
  • Vascular endothelial growth factor is one of the most potent angiogenic factors, which also induces leakage of other angiogenic factors across the endothelial cell wall into the matrix.
  • Mast cell proteases reorganize the stroma to facilitate endothelial cell migration.
  • As well, heparin, the dominant mast cell proteoglycan, assists in blood-borne metastasis. (3) Degradation of extracellular matrix: Through its own proteases, and indirectly via interaction with other cells, mast cells participate in degradation of the matrix, which is required for tumor spread. (4) Mitogenesis: Mast cell mediators including fibroblast growth factor-2 and interleukin-8 are mitogenic to melanoma cells.
  • Emerging data, however, also suggest that mast cells might, in fact, have opposing roles in tumor biology, and the microenvironment could polarize mast cells to possess either promoting or inhibitory effects on tumors.
  • [MeSH-major] Mast Cells / physiology. Skin Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / blood. Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / pathology. Humans. Melanoma / blood. Melanoma / blood supply. Melanoma / pathology. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / blood

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258517.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 71
  •  go-up   go-down


84. Varga E, Kiss M, Szabó K, Kemény L: Detection of Merkel cell polyomavirus DNA in Merkel cell carcinomas. Br J Dermatol; 2009 Oct;161(4):930-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of Merkel cell polyomavirus DNA in Merkel cell carcinomas.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive tumour for which an increasing incidence has been reported.
  • A new human polyomavirus, Merkel cell polyomavirus (MCV), was recently isolated from these tumours by applying digital transcriptome subtraction methodology.
  • METHODS: Nine primary or recurrent MCCs from seven patients were examined; 29 other tumours (squamous cell, basal cell and basosquamous carcinomas and malignant melanomas) were examined for comparative purposes.
  • [MeSH-major] Antigens, Viral, Tumor / genetics. Capsid Proteins / genetics. Carcinoma, Merkel Cell / virology. Polyomaviridae / genetics. Polyomavirus Infections / virology. Skin Neoplasms / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438857.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / Capsid Proteins
  •  go-up   go-down


85. Bugatti L, Filosa G: Dermatoscopic features of cutaneous atypical fibroxanthoma: three cases. Clin Exp Dermatol; 2009 Dec;34(8):e898-900
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical fibroxanthoma (AFX) is an uncommon, low-grade, malignant, spindle-cell tumour of fibrohistiocytic histogenesis, which can mimic other malignant skin tumours, such as basal and squamous cell carcinoma (CC), melanoma, and Merkel cell carcinoma (MCC).
  • AFX may be added to the list of slightly pigmented, reddish, malignant cutaneous tumours, such as SCC, MCC, amelanotic/hypomelanotic melanoma and eccrine porocarcinoma, which display prominent and chaotic dermatoscopic neoangiogenetic features in more advanced stages of proliferation.
  • [MeSH-major] Dermoscopy / methods. Histiocytoma, Benign Fibrous / pathology. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055861.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF: Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther; 2010 Nov-Dec;23(6):651-61
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach.
  • Electroporation uses pulsed, high-intensity electric fields to temporarily increase cell membrane permeability by creation of pores, through which small molecules, such as chemotherapeutic agents, can diffuse inside cells before they reseal.
  • ECT has already been proven to be effective in diverse tumor histotypes, including melanoma and basal and squamous cell carcinoma, Kaposi sarcoma, and breast cancer, also in those cases nonresponding to classical chemotherapies or other loco-regional treatment modalities, with a good safety profile.
  • ECT can be proposed as loco-regional therapy for disseminated cutaneous and subcutaneous tumor lesions as alternative treatment modality to conventional therapies or as palliative care, in order to improve patients' quality of life.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Electrochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Humans. Skin / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley Periodicals, Inc.
  • (PMID = 21054709.001).
  • [ISSN] 1529-8019
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


87. Jensen AO, Svaerke C, Farkas D, Pedersen L, Kragballe K, Sørensen HT: Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. Acta Derm Venereol; 2010 Sep;90(5):474-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark.
  • This study assessed the risk of skin cancer following transplantation of 4 types of solid organs, and the risk of skin cancer in patients with chronic diseases that lead to organ transplantations.
  • Linkage to the Danish Cancer Registry allowed complete follow-up for basal cell carcinoma, squamous cell carcinoma and malignant melanoma.
  • The SIR for squamous cell carcinoma was highest among heart (SIR = 113; 95% CI: 74-166), then renal (SIR = 81; 95% CI: 68-96), lung (SIR = 65; 95% CI: 28-128) and liver (SIR = 60; 95% CI: 27-113) recipients.
  • SIR for squamous cell carcinoma was 4.8 (95% CI: 2.2-9.0) among renal failure patients, but not greatly elevated among patients with the other chronic diseases studied.
  • Organ transplantation is a risk factor for squamous cell carcinoma, with immunosuppressive treatments being the most likely explanation for the association.
  • [MeSH-major] Organ Transplantation / adverse effects. Skin Neoplasms / epidemiology. Skin Neoplasms / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Child. Child, Preschool. Chronic Disease. Cohort Studies. Denmark / epidemiology. Female. Heart Diseases / epidemiology. Heart Transplantation / adverse effects. Humans. Immunosuppressive Agents / adverse effects. Incidence. Infant. Infant, Newborn. Kidney Diseases / epidemiology. Kidney Transplantation / adverse effects. Liver Diseases / epidemiology. Liver Transplantation / adverse effects. Lung Diseases / epidemiology. Lung Transplantation / adverse effects. Male. Melanoma / epidemiology. Melanoma / etiology. Middle Aged. Registries. Risk Assessment. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Derm Venereol. 2010 Sep;90(5):450-3 [20814615.001]
  • (PMID = 20814621.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


88. Krathen MS, Gottlieb AB, Mease PJ: Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol; 2010 Nov;37(11):2205-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: It is unclear if skin cancer risk is affected by the use of immunomodulatory medications in rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA).
  • METHODS: The English language literature on PubMed was searched with a combination of phrases, including "malignancy," "skin cancer," "squamous cell carcinoma," "basal cell carcinoma," "melanoma," "psoriasis," "psoriatic arthritis," and "rheumatoid arthritis" in addition to the generic names of a variety of common immunomodulatory drugs.
  • Treatment with tumor necrosis factor inhibitors increases the rates of non-melanoma skin cancer (NMSC) in RA and psoriasis.
  • Methotrexate may increase the risk of malignant melanoma in patients with RA and the risk of NMSC in psoriasis.
  • More careful recording of skin cancer development during clinical trials and cohort studies is necessary to further delineate the risks of immunomodulatory therapy.
  • [MeSH-major] Arthritis, Psoriatic / therapy. Arthritis, Rheumatoid / therapy. Immunosuppression / adverse effects. Psoriasis / therapy. Skin Neoplasms / etiology


89. Gass JK, Chan SK, Rytina E, Greenberg DC, Burrows NP: Multiple primary malignancies in patients with Merkel cell carcinoma. J Eur Acad Dermatol Venereol; 2010 May;24(5):601-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple primary malignancies in patients with Merkel cell carcinoma.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a rare malignant cutaneous tumour, the incidence of which is increasing.
  • OBJECTIVES: We report the rate and nature of multiple malignancies in patients with MCC treated over a 10 year period in Addenbrooke's Hospital in Cambridge, United Kingdom, as well as the temporal relationship of these additional malignancies to the diagnosis of MCC.
  • RESULTS: The 27 patients had an approximately equal sex incidence with a median age at diagnosis of 79 years.
  • Seventy percent (n=19) of patients had a second primary malignant tumour; and 7 of these patients had two or more tumours in addition to the MCC.
  • Eighteen patients had additional cutaneous malignancies: melanoma, squamous cell carcinoma and basal cell carcinoma, and 8 patients presented non-cutaneous malignancy including colorectal, haematological and breast tumours.
  • Of the 28 additional tumours in our patients, half were diagnosed prior to presentation of MCC, 32% within 6 months of diagnosis, and 18% between 6 months and 3 years after diagnosis.
  • CONCLUSIONS: Our figures reflect a higher incidence of multiple malignancies in those with Merkel cell tumour than has previously been reported.
  • [MeSH-major] Carcinoma, Merkel Cell / complications. Neoplasms, Multiple Primary / complications. Skin Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900177.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


90. Rizvi SA, Amitava AK, Mehdi G, Sharma R, Alam MS: Orbital amelanotic melanoma in xeroderma pigmentosum: a rare association. Indian J Ophthalmol; 2008 Sep-Oct;56(5):421-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Xeroderma pigmentosum (XP) is an autosomal recessive genetic disorder of DNA repair in which the body's normal ability to repair damage caused by ultraviolet light is deficient.
  • Ocular neoplasms occurring in XP in order of frequency are squamous cell carcinoma, basal cell carcinoma and melanoma.
  • Malignant melanomas occur at an early age in patients with XP.
  • [MeSH-major] Melanoma, Amelanotic / complications. Orbit. Skin Neoplasms / complications. Xeroderma Pigmentosum / complications
  • [MeSH-minor] Child. Diagnosis, Differential. Humans. Male. Ophthalmologic Surgical Procedures / methods

  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1974 Feb;80(2):221-48 [4811796.001]
  • [Cites] Cancer. 1982 Sep 1;50(5):912-8 [6807528.001]
  • [Cites] Arch Dermatol. 1987 Feb;123(2):241-50 [3545087.001]
  • [Cites] Tunis Med. 2006 Sep;84(9):542-4 [17263199.001]
  • [Cites] Br J Ophthalmol. 1993 Sep;77(9):597-8 [8218060.001]
  • [Cites] Br J Ophthalmol. 1994 Apr;78(4):295-7 [8199117.001]
  • [Cites] Br J Dermatol. 1965 May;77:261-76 [14283428.001]
  • [Cites] Arch Ophthalmol. 1989 Mar;107(3):402-7 [2923565.001]
  • (PMID = 18711275.001).
  • [ISSN] 0301-4738
  • [Journal-full-title] Indian journal of ophthalmology
  • [ISO-abbreviation] Indian J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2636150
  •  go-up   go-down


91. Johansen P, Berg K, Selbo PK, Hofbauer GF: [Photochemical internalisation (PCI): a further development of photodynamic therapy for the treatment of skin cancer]. Praxis (Bern 1994); 2010 Nov 17;99(23):1423-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photochemical internalisation (PCI): a further development of photodynamic therapy for the treatment of skin cancer].
  • [Transliterated title] Photochemische Internalisierung (PCI): eine Weiterentwicklung der photodynamischen Therapie zur Behandlung von Hautkrebs.
  • Recently, several new and non-invasive methods have been introduced for the treatment of skin cancers.
  • Topical creams using the immune modulator imiquimod or the COX inhibitor diclofenac (with hyaluronic acid) are now registered for use against neoplasms such as basal or squamous cell carcinoma.
  • A refined version of PDT, namely photochemical internalisation, is currently subject to a first clinical trial in patients with osteosarcoma, squamous cell carcinoma, head and neck cancer as well as adenocarcinoma of the breast.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Melanoma / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Cytosol / drug effects. Endocytosis. Endosomes / drug effects. Humans. Melanoma, Experimental / drug therapy. Mice. Neoplasm Transplantation

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21082595.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


92. Bouwes Bavinck JN, Euvrard S, Naldi L, Nindl I, Proby CM, Neale R, Abeni D, Tessari GP, Feltkamp MC, Claudy A, Stockfleth E, Harwood CA, EPI-HPV-UV-CA group: Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol; 2007 Jul;127(7):1647-56
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy.
  • This study examines the association of keratotic skin lesions with the development of skin cancer in 915 solid organ-transplant recipients in five European countries.
  • In a hospital-based case-control study, cases with squamous- and basal-cell carcinoma were compared with controls without skin cancer.
  • Questionnaires, scrutiny of medical charts, and skin examination were delivered according to a standardized protocol.
  • Keratotic skin lesions and viral warts were counted on different body sites.
  • Keratotic skin lesions were strongly associated with an increased risk of squamous-cell carcinoma, with adjusted odds ratios of 4.1 (2.4;7.0) and 12.1 (6.1;24) for 1-49 and 50 and more keratotic skin lesions compared with no lesions, respectively.
  • Keratotic skin lesions were also associated with basal-cell carcinoma with adjusted odds ratios of 2.9 (1.7;4.9) and 4.0 (1.7;9.2) for 1-49 and 50 and more lesions, respectively.
  • Lighter skin types and painful sunburns were also significantly associated with an increased risk of squamous- and basal-cell carcinoma.
  • Keratotic skin lesions are strongly associated with skin cancer and are, thus, an important clinical criterion for identifying those organ-transplant recipients at an increased risk of skin cancers who should be offered more intensive skin surveillance.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Keratosis / epidemiology. Keratosis / pathology. Skin Neoplasms / etiology. Transplantation / adverse effects
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Europe / epidemiology. Female. Humans. Life Style. Male. Middle Aged. Papillomavirus Infections / epidemiology. Risk Factors. Sex Characteristics. Skin Pigmentation. Sunlight / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):87-99 [15979889.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):307 [10642700.001]
  • [Cites] Transplantation. 2000 Jan 15;69(1):44-9 [10653378.001]
  • [Cites] J Clin Microbiol. 2000 Jun;38(6):2087-96 [10834958.001]
  • [Cites] J Med Virol. 2000 Jul;61(3):289-97 [10861635.001]
  • [Cites] Am J Kidney Dis. 2000 Jul;36(1):167-76 [10873887.001]
  • [Cites] Br J Dermatol. 2000 Sep;143(3):513-9 [10971322.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):3065-73 [11114894.001]
  • [Cites] Transplantation. 2000 Nov 27;70(10):1479-84 [11118094.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):231-8 [11134217.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] EMBO J. 2002 Sep 2;21(17):4741-8 [12198176.001]
  • [Cites] Br J Dermatol. 2002 Nov;147(5):950-6 [12410706.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Acta Otolaryngol. 2005 Sep;125(9):991-8 [16193590.001]
  • [Cites] Acta Derm Venereol. 2003;83(3):189-93 [12816154.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):890-4 [12873884.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] Arch Dermatol Res. 2003 Dec;295(7):273-9 [14618345.001]
  • [Cites] J Invest Dermatol. 2003 Dec;121(6):1531-5 [14675206.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1540-3 [14693751.001]
  • [Cites] N Engl J Med. 2004 Jun 24;350(26):2639-42 [15215478.001]
  • [Cites] Science. 2005 Sep 16;309(5742):1871-4 [16166520.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2695-700 [12750299.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 15;98(6):389-95 [16537831.001]
  • [Cites] Br J Dermatol. 2006 Mar;154(3):498-504 [16445782.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1079-85 [15381547.001]
  • [Cites] J Invest Dermatol. 2005 Jul;125(1):93-7 [15982308.001]
  • [Cites] J Clin Microbiol. 1999 Nov;37(11):3545-55 [10523550.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] J Invest Dermatol. 1995 Sep;105(3):367-71 [7665914.001]
  • [Cites] Br J Dermatol. 1993 Sep;129(3):242-9 [8286220.001]
  • [Cites] N Engl J Med. 1991 Sep 19;325(12):843-8 [1875968.001]
  • [Cites] Acta Derm Venereol. 1990;70(6):491-4 [1981421.001]
  • [Cites] Transplantation. 1990 Mar;49(3):506-9 [2316011.001]
  • [Cites] Q J Med. 1987 Jul;64(243):609-16 [3313494.001]
  • [Cites] Lancet. 1984 Mar 31;1(8379):702-5 [6143041.001]
  • (PMID = 17380113.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6695
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2478722; NLM/ UKMS1916
  •  go-up   go-down


93. Caccialanza M, Piccinno R, Kolesnikova L, Gnecchi L: Radiotherapy of skin carcinomas of the pinna: a study of 115 lesions in 108 patients. Int J Dermatol; 2005 Jun;44(6):513-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy of skin carcinomas of the pinna: a study of 115 lesions in 108 patients.
  • BACKGROUND: The possibility of treating skin carcinomas of the pinna with radiotherapy is somewhat under discussion and scarcely known.
  • Therefore the aim of the study was to evaluate the effectiveness and safety of dermatologic radiotherapy in a series of patients affected by basal or squamous cell carcinoma of the pinna.
  • METHODS: A retrospective study was performed on 108 patients affected by 115 carcinomas of the pinna (99 basal cell carcinomas, 16 squamous cell carcinomas) without involvement of the external auditory canal.
  • During follow up a relapse was observed in 12 lesions (all basal cell carcinomas): nine central and three marginal to the irradiation field.
  • CONCLUSIONS: The results obtained confirm the possibility of treating epithelial skin neoplasms of the pinna with dermatologic radiotherapy, which can afford high-remission percentages without damaging cartilaginous tissue.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Ear Neoplasms / radiotherapy. Ear, External. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Esthetics. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941445.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Tarallo M, Cigna E, Frati R, Delfino S, Innocenzi D, Fama U, Corbianco A, Scuderi N: Metatypical basal cell carcinoma: a clinical review. J Exp Clin Cancer Res; 2008;27:65
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for metatypical basal cell carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metatypical basal cell carcinoma: a clinical review.
  • BACKGROUND: Metatypical cell carcinoma can be considered as a new entity of skin cancer, being an intermediate typology between basal cell carcinomas and squamous cell carcinomas.
  • The behaviour of the metatypical cell carcinoma lies between these two varieties of skin cancer.
  • It is difficult to perform a differential diagnosis based on morphological and clinical features - therefore it is only possible by accurate histology.
  • METHODS: The authors have retrospectively analysed clinical records of 240 patients who were affected by metatypical skin cancer and who were treated by surgery, radiotherapy and chemotherapy.
  • CONCLUSION: In this manuscript, the authors have emphasised the importance of conducting a differential diagnosis, and the importance of the specific treatment for metatypical skin cancer, even though more clinical studies and long-term follow-ups are required before establishing specific guidelines.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):224-30 [11174379.001]
  • [Cites] Plast Reconstr Surg. 2001 Apr 1;107(4):942-7 [11252086.001]
  • [Cites] Plast Reconstr Surg. 2002 Apr 1;109(4):1466-7 [11965016.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):551-8 [12461611.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 May;128(5):663-73 [12748559.001]
  • [Cites] Dermatol Surg. 2003 Jul;29(7):700-11 [12828693.001]
  • [Cites] Dermatol Surg. 2003 Aug;29(8):830-2; discussion 833 [12859383.001]
  • [Cites] J Craniomaxillofac Surg. 2004 Feb;32(1):16-8 [14729044.001]
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):248-52 [14871217.001]
  • [Cites] Br J Ophthalmol. 2004 Mar;88(3):358-60 [14977769.001]
  • [Cites] Acta Derm Venereol. 2004;84(1):44-7 [15040477.001]
  • [Cites] Arch Facial Plast Surg. 2004 May-Jun;6(3):158-61 [15148122.001]
  • [Cites] Br J Oral Maxillofac Surg. 2004 Aug;42(4):311-4 [15225948.001]
  • [Cites] Arch Dermatol. 1965 Dec;92(6):635-7 [5846318.001]
  • [Cites] Br J Dermatol. 1973 Jul;89(1):37-43 [4788317.001]
  • [Cites] Ophthalmologica. 1983;187(1):51-8 [6877760.001]
  • [Cites] Arkh Patol. 1983;45(6):35-9 [6625927.001]
  • [Cites] J Am Acad Dermatol. 1984 Oct;11(4 Pt 1):557-62 [6490979.001]
  • [Cites] Dermatologica. 1985;171(1):21-6 [2411609.001]
  • [Cites] Arch Dermatol. 1987 Mar;123(3):340-4 [3813602.001]
  • [Cites] J Dermatol Surg Oncol. 1987 May;13(5):556-7 [3571694.001]
  • [Cites] J Dermatol Surg Oncol. 1988 Jun;14(6):600-2 [3372843.001]
  • [Cites] Dermatol Clin. 1988 Jul;6(3):397-405 [3048822.001]
  • [Cites] Mod Pathol. 1991 May;4(3):325-30 [2068058.001]
  • [Cites] J Am Acad Dermatol. 1992 Jan;26(1):1-26 [1732313.001]
  • [Cites] Pathol Res Pract. 1991 Dec;187(8):978-85 [1792194.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8 [1430364.001]
  • [Cites] J Invest Dermatol. 1994 Jun;102(6):6S-9S [8006441.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):667-73 [7804993.001]
  • [Cites] Arkh Patol. 1994 Jul-Aug;56(4):35-8 [7848103.001]
  • [Cites] Ann Chir Plast Esthet. 1994 Apr;39(2):176-83 [7872634.001]
  • [Cites] Am J Surg. 1995 Nov;170(5):446-50 [7485729.001]
  • [Cites] Laryngoscope. 1996 Feb;106(2 Pt 1):156-8 [8583845.001]
  • [Cites] Am J Dermatopathol. 1996 Feb;18(1):35-42 [8721589.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):279-81; discussion 281-2 [9218319.001]
  • [Cites] J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):430-7 [9308559.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):627-36 [9342506.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):673-86 [9342510.001]
  • [Cites] J Cutan Pathol. 1998 Mar;25(3):153-9 [9550314.001]
  • [Cites] Br J Plast Surg. 1999 Jan;52(1):24-8 [10343586.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Semin Cutan Med Surg. 2004 Sep;23(3):167-73 [15584682.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):170-5 [15929123.001]
  • [Cites] Br J Plast Surg. 2005 Sep;58(6):795-805 [16086990.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):464-8 [16112354.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2007;60(1):41-7 [17126265.001]
  • [Cites] Eur J Dermatol. 2000 Jun;10(4):315-6 [10939863.001]
  • [Cites] Br J Oral Maxillofac Surg. 2000 Oct;38(5):477-9 [11010777.001]
  • [Cites] J Natl Compr Canc Netw. 2004 Jan;2(1):2 [19777690.001]
  • (PMID = 18992138.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 55
  • [Other-IDs] NLM/ PMC2585560
  •  go-up   go-down


95. Norval M, Cullen AP, de Gruijl FR, Longstreth J, Takizawa Y, Lucas RM, Noonan FP, van der Leun JC: The effects on human health from stratospheric ozone depletion and its interactions with climate change. Photochem Photobiol Sci; 2007 Mar;6(3):232-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solar UVR has many harmful and some beneficial effects on individuals and, in this review, information mainly published since the previous report in 2003 (F. R. de Gruijl, J.
  • Takizawa and J. C. van der Leun, Photochem. Photobiol.
  • Studying how UV-B interacts with the surface and internal structures of the eye has led to a further understanding of the location and pathogenesis of a number of ocular diseases, including pterygium and cataract.
  • The skin is also exposed directly to solar UVR, and the development of skin cancer is the main adverse health outcome of excessive UVR exposure.
  • Skin cancer is the most common form of malignancy amongst fair-skinned people, and its incidence has increased markedly in recent decades.
  • Several of the genetic factors affecting susceptibility to the development of squamous cell carcinoma, basal cell carcinoma and melanoma have been identified.
  • Exposure to solar UVR down-regulates immune responses, in the skin and systemically, by a combination of mechanisms including the generation of particularly potent subsets of T regulatory cells.
  • Such immunosuppression is known to be a crucial factor in the generation of skin cancers.
  • Various strategies that can be adopted by the individual to protect against excessive exposure of the eye or the skin to sunlight are suggested.
  • [MeSH-minor] Animals. Eye / metabolism. Eye / radiation effects. Humans. Skin / metabolism. Skin / radiation effects. Vitamin D / metabolism


96. Mitsuhashi T, Itoh T, Shimizu Y, Ban S, Ogawa F, Hirose T, Shimizu M: Squamous cell carcinoma of the skin: dual differentiations to rare basosquamous and spindle cell variants. J Cutan Pathol; 2006 Mar;33(3):246-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the skin: dual differentiations to rare basosquamous and spindle cell variants.
  • Basosquamous carcinoma (BSC) is defined as a tumor containing the areas of both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) with a transition zone linking the two.
  • Spindle cell squamous carcinoma (SCSC) may have a variable component of conventional SCC and spindle cells.
  • Grossly, the lesion measured 8.5 x 6.0 x 1.8 cm and consisted of a gray-white and focally black tumor.
  • Microscopically, a non-ulcerated upper part of the tumor consisted of large polygonal squamoid cells with occasional keratinization (SCC), trabecular growth of basaloid cells with peripheral palisading (BCC), and an area in which both the components were intermingled.
  • The rest of the tumor was a myxoid area with elongated fusiform spindle cells, which appeared to arise from conventional SCC.
  • Immunohistochemically, the tumor cells in the SCSC (both conventional and spindle cell) area co-expressed CAM5.2, and vimentin.
  • Ber-EP4 was positive in the BCC area with the transition zone of SCC and BCC showing diminished staining.
  • To our knowledge, this is the first case report of SCC of the skin that has dual differentiations to BSC and SCSC.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Female. Humans. Immunohistochemistry. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466514.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


97. Padgett JK: Cutaneous lesions: benign and malignant. Facial Plast Surg Clin North Am; 2005 May;13(2):195-202, v
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous lesions: benign and malignant.
  • This article reviews the clinical characteristics, histology, biologic behavior, and recommended treatment for several benign and malignant lesions that may arise on the head and neck.
  • Basal and squamous cell carcinoma, lentigo maligna and lentigo maligna melanoma, dermatofibrosarcoma protuberans, and Merkel cell carcinoma are malignant lesions for which surgical excision is the recommended treatment.
  • Local flap reconstruction may be used to address the surgical defects resulting from excision of these benign and malignant conditions.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / surgery. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / surgery. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / surgery. Humans. Hutchinson's Melanotic Freckle / diagnosis. Hutchinson's Melanotic Freckle / surgery. Nevus, Pigmented / diagnosis. Nevus, Pigmented / surgery. Risk Factors. Scalp. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15817400.001).
  • [ISSN] 1064-7406
  • [Journal-full-title] Facial plastic surgery clinics of North America
  • [ISO-abbreviation] Facial Plast Surg Clin North Am
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


98. Verhoeven RH, Louwman WJ, Koldewijn EL, Demeyere TB, Coebergh JW: Scrotal cancer: incidence, survival and second primary tumours in the Netherlands since 1989. Br J Cancer; 2010 Oct 26;103(9):1462-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The overall incidence rate varied around 1.5 per 1,000,000 person-years, most frequently being squamous cell carcinoma (27%), basal cell carcinoma (19%) and Bowen's disease (15%).
  • Overall 5-year relative survival was 82%, being 77% and 95% for patients with squamous and basal cell carcinoma, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] Urology. 2008 Nov;72(5):1139-43 [18799208.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):33-9 [12077578.001]
  • [Cites] J Urol. 1967 Jul;98(1):108-10 [6067877.001]
  • [Cites] Br J Ind Med. 1972 Apr;29(2):188-95 [5063206.001]
  • [Cites] Acta Derm Venereol. 1974;54(6):471-4 [4140663.001]
  • [Cites] Ann N Y Acad Sci. 1976;271:138-42 [1069495.001]
  • [Cites] J Urol. 1977 Jun;117(6):741-5 [559784.001]
  • [Cites] Urology. 1982 Mar;19(3):269-74 [7064253.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):596-601 [6733690.001]
  • [Cites] Br J Ind Med. 1984 Nov;41(4):437-44 [6498107.001]
  • [Cites] Cancer. 1985 Feb 1;55(3):666-71 [3965115.001]
  • [Cites] Comput Programs Biomed. 1985;19(2-3):197-207 [3839736.001]
  • [Cites] Am J Public Health. 1989 Nov;79(11):1513-5 [2817163.001]
  • [Cites] Br J Ind Med. 1989 Jun;46(6):430-1 [2818983.001]
  • [Cites] Br J Urol. 1991 Oct;68(4):414-7 [1933164.001]
  • [Cites] J Urol. 1991 Nov;146(5):1299-304 [1942281.001]
  • [Cites] Cancer Causes Control. 1992 Jan;3(1):91-3 [1536920.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2759-64 [8194017.001]
  • [Cites] Occup Med (Lond). 1996 Feb;46(1):69-70 [8672799.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Mar;109(2):108-13 [10087941.001]
  • [Cites] AMA Arch Ind Health. 1959 May;19(5):530-9 [13636468.001]
  • [Cites] Br J Ind Med. 1972 Oct;29(4):394-406 [15625750.001]
  • [Cites] Ned Tijdschr Geneeskd. 2006 May 20;150(20):1108-15 [16756222.001]
  • [Cites] Arch Dermatol. 2000 Dec;136(12):1524-30 [11115165.001]
  • (PMID = 20877361.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2990603
  •  go-up   go-down


99. Dim-Jamora KC, Perone JB: Management of cutaneous tumors with mohs micrographic surgery. Semin Plast Surg; 2008 Nov;22(4):247-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We discuss the use of Mohs micrographic surgery for the following cutaneous tumors: basal cell carcinoma, squamous cell carcinoma, melanoma in situ, dermatofibrosarcoma protuberans, Merkel cell carcinoma, microcystic adnexal carcinoma, atypical fibroxanthoma, and sebaceous carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1996 Mar 16;347(9003):735-8 [8602006.001]
  • [Cites] J Am Acad Dermatol. 1996 Jul;35(1):82-7 [8682970.001]
  • [Cites] J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):233-6 [7829708.001]
  • [Cites] Lancet. 1994 Feb 19;343(8895):433-4 [7905951.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2964-70 [8199993.001]
  • [Cites] Clin Plast Surg. 1993 Jan;20(1):149-56 [8420703.001]
  • [Cites] J Am Acad Dermatol. 1993 Nov;29(5 Pt 2):840-5 [8408823.001]
  • [Cites] Otolaryngol Clin North Am. 1993 Apr;26(2):185-202 [8460037.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Aug;17(8):681-4 [1885833.001]
  • [Cites] Dermatol Clin. 1989 Oct;7(4):833-43 [2676291.001]
  • [Cites] Dermatol Clin. 1989 Oct;7(4):609-11 [2676280.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] N J Med. 1989 May;86(5):369-73 [2739948.001]
  • [Cites] J Am Acad Dermatol. 1986 Apr;14(4):668-73 [3958277.001]
  • [Cites] Eye (Lond). 1990;4 ( Pt 1):160-8 [2323467.001]
  • [Cites] Head Neck Surg. 1983 Jan-Feb;5(3):197-203 [6841116.001]
  • [Cites] Arch Dermatol. 1974 Aug;110(2):231-2 [4853214.001]
  • [Cites] Plast Reconstr Surg. 2004 Jun;113(7):2233; author reply 2233-4 [15253235.001]
  • [Cites] Arch Dermatol. 2004 Jun;140(6):736-42 [15210467.001]
  • [Cites] Clin Plast Surg. 2004 Jan;31(1):5-31 [15022790.001]
  • [Cites] Plast Reconstr Surg. 2002 Nov;110(6):1601 [12409793.001]
  • [Cites] Dermatol Surg. 2002 Aug;28(8):656-65 [12174054.001]
  • [Cites] Semin Oncol. 2002 Aug;29(4):336-40 [12170436.001]
  • [Cites] Dermatol Surg. 2002 Jul;28(7):623-31 [12135523.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):18-25 [11841362.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):579-86 [11568750.001]
  • [Cites] Arch Facial Plast Surg. 2001 Jul-Sep;3(3):202-6 [11497507.001]
  • [Cites] J Am Acad Dermatol. 2001 Jun;44(6):1004-9 [11369914.001]
  • [Cites] Dermatol Surg. 2001 Apr;27(4):401-8 [11298716.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):771-84 [10940065.001]
  • [Cites] Dermatol Surg. 2000 Apr;26(4):303-7 [10759814.001]
  • [Cites] Aust N Z J Surg. 2000 May;70(5):358-61 [10830600.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1842-51 [10760761.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):395-402 [17430372.001]
  • [Cites] Skin Therapy Lett. 2007 Mar;12(2):6-9 [17393051.001]
  • [Cites] Ophthalmology. 2007 Jan;114(1):187-92 [17140665.001]
  • [Cites] Arch Dermatol. 2006 Feb;142(2):187-94 [16490846.001]
  • [Cites] Dermatol Surg. 2005 Nov;31(11 Pt 1):1428-33 [16416612.001]
  • [Cites] Dermatol Surg. 2005 Sep;31(9 Pt 1):1094-9; discussion 1100 [16164856.001]
  • [Cites] Curr Surg. 2005 Sep-Oct;62(5):518-26 [16125611.001]
  • [Cites] Arch Facial Plast Surg. 2005 Sep-Oct;7(5):342-6 [16172346.001]
  • [Cites] J Craniofac Surg. 2005 May;16(3):439-43 [15915111.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):10-5 [15720088.001]
  • [Cites] Dermatol Surg. 2004 Dec;30(12 Pt 1):1479-85 [15606735.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Am J Otolaryngol. 2004 Nov-Dec;25(6):385-93 [15547806.001]
  • [Cites] J Am Acad Dermatol. 1998 Nov;39(5 Pt 1):698-703 [9810885.001]
  • [Cites] Semin Cutan Med Surg. 1998 Jun;17(2):80-95 [9669602.001]
  • [Cites] J Am Acad Dermatol. 1998 Jul;39(1):79-97 [9674401.001]
  • [Cites] Dermatol Surg. 1997 Nov;23(11):1061-6 [9391565.001]
  • [Cites] Dermatol Surg. 1997 Oct;23(10):929-33 [9357504.001]
  • [Cites] Dermatol Surg. 1997 Feb;23(2):105-10 [9107284.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):1-15; quiz 16-8 [7601925.001]
  • (PMID = 20567701.001).
  • [ISSN] 1536-0067
  • [Journal-full-title] Seminars in plastic surgery
  • [ISO-abbreviation] Semin Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2884874
  • [Keywords] NOTNLM ; Mohs micrographic surgery / cutaneous oncology / skin cancer
  •  go-up   go-down


100. Filip A, Clichici S, Daicoviciu D, Adriana M, Postescu ID, Perde-Schrepler M, Olteanu D: Photochemoprevention of cutaneous neoplasia through natural products. Exp Oncol; 2009 Mar;31(1):9-15
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-melanoma skin cancers such as squamous cell carcinoma and basal cell carcinoma are the most common types of human tumors, representing 30% of the new cases of malignancies diagnosed each year.
  • Ultraviolet radiation (UV) from the sun is a major cause of non-melanoma skin cancer in humans.
  • Here we review the progress in the research of new and existing agents developed to protect the skin exposed to UV.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Cat's Claw. Flavonoids / therapeutic use. Phenols / therapeutic use. Phytotherapy. Polypodium. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300410.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Flavonoids; 0 / Phenols; 0 / Plant Preparations; 0 / Polyphenols; 0 / Silymarin; 4RKY41TBTF / silybin
  • [Number-of-references] 62
  •  go-up   go-down






Advertisement